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Introduction 
 
Thirty-six researchers and national coordinators and programme managers of 
schistosomiasis and HIV/STD control programmes from west, east and southern Africa, 
Europe and USA gathered at the Taj Pamodzi Hotel in Lusaka, Zambia, to discuss the 
impact of genital schistosomiasis on public health and its implications for national 
programmes for the control of schistosomiasis, HIV/AIDS and sexually transmitted 
diseases. 
 
 
Background 
  
Research in the field of genital schistosomiasis has given rise to the hypotheses that 
there might be a relationship between genital schistosomiasis and transmission of HIV, 
female infertility and morbidity.  
 
Research has shown that women suffering from genital schistosomiasis have genital 
sandy patches and contact bleeding. There are several case reports discussing the 
possible causative association between genital schistosomiasis and cervical dysplasia 
and/or human papillomavirus. Furthermore, there is a recent study indicating that 
genital schistosomiasis may be refractory to treatment in adults. 
 
Conducting research in genital schistosomiasis poses huge challenges. One major 
challenge is the difficulties in diagnosing genital schistosomiasis. The commonly used 
diagnostic tools such as urine filtration and faecal Kato-Katz have been proven to be 
insufficient in diagnosing genital schistosomiasis. The ova are located in highly focal 
clusters and may be missed in a biopsy, especially with histological sectioning of a 
biopsy. Moreover, taking a biopsy for the diagnosis of genital S. haematobium infection 
remains an HIV transmission risk for the patient and her partner until the inflicted 
wound has healed, raising ethical concern. Wet smears and PAP smears make a 
contribution to the diagnosis but the sensitivity is low.  
 
 
Objectives and form 
 
The overall objective of the workshop was to bring together researchers, national 
coordinators and programme managers with a relevant background to identify and 
discuss the impact of genital schistosomiasis on public health and its implications for 
national control programmes for HIV and STD as well as to identify future research 
needs and priorities.  
 
A number of speakers were requested to present their recent and ongoing research 
covering the topics listed below. Participants were then given the opportunity to discuss 
and make recommendations for control of genital schistosomiasis in existing control 
programmes for schistosomiasis, HIV and STDs.  
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Content and topics 
 
The workshop addressed the following topics: 
• genital schistosomiasis as a public health problem 
the possible association with HIV  
the possible association with other STDs (and possible indirect effect on 
cervical cancer) 
the possible effect of genital schistosomiasis on fertility and sexual 
behaviour  
• diagnosis of genital schistosomiasis 
• challenges in doing research on genital schistosomiasis 
research in adolescents and children 
immunological aspects of the transmission of HIV in the presence of 
schistosome eggs 
• treatment of genital schistosomiasis 
 
 
 
 
Outdoor toys are handed over to Kamulanga Primary School 
 
 
Visit to school health programme 
 
Thursday afternoon all participants went to John Howard Township to visit the 
Kamulanga Primary School, funded by the Japanese government. The school had 
approximately 1300 students which all underwent the school programme on 
“Schistosomiasis, soil transmitted helminths and HIV/AIDS control”. Nutrition and 
personal hygiene were one of the buss words in the school programme, which among 
others revealed committment from the students to keep the toilet facilities and school 
area clean as well as to care for their personal hygiene. The school grew vegetables and 
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fruit to support the nutrition of the students and made home visits to provide family 
members with the same knowledge as their children. Furthermore, there was great focus 
on information on schistosomiasis, STH and HIV/AIDS through role plays, songs, 
drama, etc. In appreciation of the visit, the workshop sponsored footballs, hand-net and 
basket balls, jumping ropes and basket nets to the school. 
 
 
Opening session 
 
The workshop was officially opened by the Honorable Minister of Health, Dr B. 
Chituwo, Ministry of Health, Zambia and Dr N. Oernbjerg, Director of DBL. Dr J. Mwanza 
from the Zambia Bilharzia Control Programme chaired the workshop trough the opening 
session. The Honorable Minister of Health said that 2 million have schistosomiasis in 
Zambia, most of whom are mothers and children. Research is important in the Zambian 
decision making processes, and hopefully the affected communities will notice that we 
have held this consultation.  
 
 
Conclusions and recommendations 
 
Schistosoma haematobium frequently causes lesions in the urogenital organs. Gross 
haematuria and dysuria are commonly reported urinary tract symptoms, whereas pelvic 
pain and vaginal discharge in women and ejaculation discomfort in men are observed in 
genital schistosomiasis.  
 
Female genital schistosomiasis is associated with HIV infection. The underlying 
mechanism is thought to be the egg-induced friable genital mucosa making women 
susceptible during intercourse with an HIV positive partner. Moreover, in men with 
HIV and S. haematobium co-infections, the inflammatory responses to egg deposition in 
the prostate or the seminal vesicles have been hypothesized to cause increased viral 
shedding in semen and may increase the risk of transmitting HIV.  
 
It is essential that treatment for schistosomiasis is provided to children in all endemic 
areas for schistosomiasis transmission to prevent the complications and repercussions of 
the disease. All opportunities for treatment should be provided including preventative 
chemotherapy through mass administration complemented by availability of 
praziquantel in health centres and STI clinics. Health care providers in schistosomiasis 
endemic areas should be further sensitized to the symptoms, risks, treatment, and 
prevention of schistosomiasis and to the link between schistosomiasis and HIV 
infection. 
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Research priorities in female (FGS) and male (MGS) genital schistosomiasis 
 
Evidence suggests that FGS is associated with HIV infection, and a similar association 
has been hypnotized for MGS. However, to turn evidence of an association into proof, 
and to document causative relationships and involved mechanisms, require further and 
comprehensive studies. A full understanding of the association between genital 
schistosomiasis and HIV require further elucidation of various aspects related to genital 
schistosomiasis as such, including diagnosis, clinical features and morbidity, treatment 
regimens and disease perceptions. 
 
The possible interaction between HIV and genital schistosomiasis is complex and other 
sexually transmitted diseases (STI), age- and sex-related differences in water contact 
patterns, and differences in socio-cultural factors and economic living conditions are 
significant confounders. This results in the need for large population based longitudinal 
studies with complicated study designs including multiple drug treatment regimens, pre- 
and post treatment analysis, and a thorough analysis of socio-cultural factors and 
economic living conditions. Introduction of a schistosomiasis component in ART (anti 
retroviral treatment) studies seems a natural way forward. 
 
Research priorities are as follows: 
 
Morbidity, diagnosis and treatment of genital schistosomiasis 
 
• Documentation of FGS and MGS as courses of reproductive tract morbidity 
with a focus on high intensity infections 
• Studies on the role of FGS and MGS in primary and secondary infertility 
• Further exploitations of clinical findings and manifestations in FGS, 
including optimisation of methods to identify sandy patches and other 
pathological manifestations and standardisation of clinical registrations and 
questionnaires 
• Further studies on clinical findings and manifestations in MGS 
• People’s perception of FGS and MGS in the light of STIs as a significant 
confounder with a focus on symptoms and clinical manifestations 
• Development of a sensitive, specific and widely accepted “gold standard” 
diagnostic technique for FGS and MGS, including the use of PRC and Elisa-
ECP techniques on vaginal lavage specimens and optimisation of sampling 
techniques 
• Optimising treatment regimes in FGS to address the proposed irreversibility 
of morbidity in adults and assessment of the effect of treatment in girls and 
young adults with different  drug dosages  
• Effect of praziquantel treatment in HIV positive individuals and further 
studies on the effect of treatment on symptoms and lesions in both MGS and 
FGS 
• An analysis of the possible relevance of cryotherapy in treatment of genital 
tract pathology in FGS 
• Further elucidation of the proposed spermatogenic apoptosis in MGS and its 
potential effect on fertility and reproductive health in men 
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Association between  genital schistosomiasis, HIV infection and other STIs 
 
• Confirmative studies that FGS predisposes to HIV infection and other STIs 
• Further documentation that  MGS may constitute a risk factor for HIV 
transmission 
 
 
Immunological and other laboratory based studies to reveal mechanisms involved in 
the association between genital schistosomiasis and HIV infection 
 
• Analysis of the possible role of angiogenesis, neovascularisation  and increased 
levels of HIV receptors in genital lesions, in schistosome egg granolomas and in 
peripheral blood for the increased susceptibility to HIV in FGS 
 
• An analysis of the HIV viral load  in semen to document whether MGS due to 
egg induced inflammation in the prostate and seminal vesicles constitutes a risk 
factor for HIV transmission 
 
• Elucidation of the possible role of a shift in the Th1/Th2 balance in individuals 
carrying both genital schistosomiasis and HIV infections in the increased 
susceptibility to HIV infection 
 
 
Health Systems Research 
 
• An analysis of appropriateness, feasibility and cost-effectiveness of introducing 
praziquantel treatment in STI clinics and other reproductive health facilities and 
services with a focus on anti-STI regimens in young women 
 
 
 
Summary of the discussions 
Epidemic Aspects of Genital Schistosomiasis with Respect to HIV 
Dr Alex Simwanza from the Zambian National Aids Council presented the HIV 
epidemic in Zambia which shows the same disproportion of affected females as 
compared to males (18% and 13%, respectively) as the rest of sub Saharan Africa. 
Several studies on HIV prevalence have shown an unexplained gender quotient 
disfavouring rural women. In rural areas the differences between men and women is 
larger than in urban areas, with up to 6.4 HIV positive women to every man. Women 
from rural areas also have an HIV prevalence peak at younger ages. Hence risk factors 
in rural and urban populations may be different. In rural areas the difference between 
the young men and women (15-24 years) is even larger. In young women the HIV 
prevalence may be up to 8 times higher than in young men. In Africa, women have been 
found to be at a higher risk of HIV per sexual intercourse with an HIV positive person 
than heterosexual men. 
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Dr Simwanza reported that the Northern Province of Zambia is the least affected (8%) 
whereas the copper belt and Lusaka have 20 and 22% in prevalence, respectively. 
Condom use is 38%, and 20% will still have sex with a non-partner. PMTCT 
(prevention of mother-to-child transmission) is very low, being 22% and 8%) 
respectively. Knowledge of the infection is as high as 98%, but ART coverage is  only 
46% (of those who need it). ART has been rolled out after these figures were calculated. 
Dr Simwanza showed an extensive organisation chart where youth and religious groups 
as well as the private sector and NGOs are working with the National Aids Council.  
 
The Social Aspects of Female Genital Schistosomiasis 
Dr Heba Ali presented an interdisciplinary study on genital schistosomiasis in Egypt. 
The study attempted to draw on the approach that places reproductive health in a social 
and cultural context, where reproductive health is viewed as ‘the ability of women to 
live through the reproductive years and beyond with reproductive choice, dignity, and 
successful childbearing, and to be free of gynaecological disease and risk’ (Kattab 
1999). 
 
The study area was a remote village in the El Faiyum Hamlet where many had protected 
water, but where washing was still done in the canals. Many women had been treated by 
the Ministry of Health in mass treatment campaigns with praziquantel. Through focus 
group discussions and interviews it was found that abortions had been experienced by 
33%, neonatal mortality by 33%, still births by 8% and 5% were infertile. Reproductive 
health problems were not discussed in the population. Urinary schistosomiasis 
prevalence was 17% (21/122). Female genital schistosomiasis (FGS) was defined as 
having at least one schistosome egg in cervical biopsy or sandy patches in the vagina or 
in the cervix. FGS was found in 50% of the infected women. These had more contact 
bleeding, erosions, polyps/ papillomata and leukoplakia than women without FGS.  
 
Dr Ali pointed out that the study was designed as a small-scale pilot study and had some 
limitations. A single quantitative urine examination for Schistosoma haematobium is not 
sufficient, especially since mass therapy campaigns had been administered prior to the 
study. It can thus be assumed that the observed prevalence of schistosomiasis was an 
underestimation of the true prevalence in the study population. FGS may also have been 
underestimated due to the fact that the biopsies were rather small (< 5mm) due to the 
fear of bleeding from the biopsy sites, and due to the fact that the gynaecologists were 
reluctant to take them from sites suspicious of pathology. In addition, for ethical 
reasons, biopsies were not taken from the vagina or vulva.  
 
She concluded that more research is needed to explore the association between 
schistosomiasis and reproductive morbidity. Furthermore, health care workers need 
training in the methods of detection and diagnosing FGS. Qualitative research is needed 
in order to better understand people’s perception about this disease entity. Increasing 
health awareness among the population should follow. Moreover, the development of 
sensitive, specific and widely acceptable diagnostic techniques is urgently needed for 
any future clinical and epidemiological research into FGS. 
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Discussion: The biopsies should be avoided, and other objective diagnostic procedures 
for genital schistosomiasis are needed. Dr. Ali was asked about the differential 
diagnosis and the other causes for reproductive tract morbidity and replied that a limited 
number of tests were done for STIs (sexually transmitted infections). She pointed out 
that the village was remote and they had not expected sexually transmitted diseases. 
However 8% were found to have syphilis so there could have been a potential for 
further exploration of the association between FGS and STIs.  
 
Female Genital Schistosomiasis Clinical Findings and Manifestations 
Dr. Kjetland presented clinical work done in rural Zimbabwe with Blair Research 
Institute. Gynaecological and laboratory investigations for S. haematobium and STIs 
were performed in 527 women between the age of 20 and 49. The aim of the study was 
to describe the prevalence of gynaecological S. haematobium infection (FGS) and to 
differentiate FGS from STIs. Homogenous yellow and/ or grainy sandy patches, the 
commonest type of pathology in the genital tract, were identified in 243 (46%) women. 
Grainy sandy patches were significantly associated with S. haematobium ova only. 
Genital S. haematobium ova presence was also significantly associated with 
homogenous yellow sandy patches, mucosal bleeding, and abnormal blood vessels. Ova 
presence was not associated with ulcers, papillomata, leukoplakia, polyps, or cell atypia. 
Urinary ova excretions decreased with age, however, genital schistosomal lesions were 
found at equal prevalence levels in all age groups. If lesions are touched with a spatula 
‘crepitations’ may be heard as the spatula moves over the sandy areas.  
 
In conclusion, genital schistosomiasis may cause sandy patches, mucosal fragility and 
bleeding, and is probably chronic after the age of 20 years. Most cases would be missed 
if only urinary analyses were done.  
 
Dr B. Randrianasolo (Madagascar) started off by acknowledging Professor Feldmeier 
and others who had brought attention to FGS as a neglected tropical disease entity. Dr 
Randrianasolo presented results from a clinical study conducted in two villages in 
Madagascar; Sirama (S. haematobium high-endemic, >50%) and Mataipako (<20%, 
low-endemic). The two villages were comparable in other aspects. The study aimed to 
explore the symptoms and clinical manifestations in the lower genital tract of sexually 
transmitted diseases. According to the study design praziquantel treatment was delayed 
for one month whilst women were treated for STIs. Symptoms and disappearance of 
symptoms were recorded at baseline (before any treatment), 1 month (after treatment of 
STIs only) and at 6 months (after treatment with praziquantel). 
 
In the high-endemic schistosomiasis village only people with urinary schistosomiasis 
were included (n=147) and in the low-endemic village only people where no S. 
haematobium eggs were detected in urine were included (n=106). At baseline 
neovascularisations and inflammatory lesions were found significantly more often in the 
schistosomiasis endemic village. There was however no difference in the prevalence of 
sandy patches among the 2 villages (6% vs. 2%). Surprisingly, in the S. haematobium 
endemic area, there was less tenderness upon bimanual palpation of the uterus (6% vs. 
22%, p<0.001) and there was significantly less “rough aspect of the cervix surface” 
(11% vs. 21%, p=0.03). After treatment (n=115) there were minor decreases in sandy 
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patches: 6/157 (3.8%) vs. 1/64 (1.4%) and neovascularisation: 17/157 (10.8%) vs. 4/64 
(6.3%). Dr Randrianasolo reported that sandy patches are difficult to visualise and may 
have been overlooked in the study. Contact bleeding had not been recorded.  
 
In this comprehensive study, Dr Randrianasolo found that 50% of the women co-
infected with STIs and schistosomiasis had no subjective complaints. Although there 
was no difference in occurrence of STIs in the 2 villages in the schistosomiasis endemic 
village women reported significantly more pelvic discomfort (p< 0.001), dysuria 
(p<0.05) and gross haematuria (p<0.05) in the highly endemic village. This difference 
between the 2 villages remained after all the STIs had been treated at the 1-month 
inspection.  
 
There was no difference between the schistosomiasis endemic and non-endemic areas 
with respect to discharge, dyspareunia, vulval itch and postcoital bleeding. However, 
upon closer analysis looking at intensity of urinary schistosomiasis infection (less or 
more than 50 ova/10mL urine) dyspareunia was found more often in women with high-
intensity infections (p=0.07).  
 
Discussion: Symptoms may be difficult to differentiate from the sexually transmitted 
diseases (eg. dysuria in both cases). The genital examination is complicated in the rural 
setting and the lack of good light, magnification and stirrups may make it difficult to see 
the lesions. It is therefore important to look for less complicated ways of identifying 
sandy patches.  
 
In Niger, 25% of the population is at risk of schistosomiasis. Dr Garba (Niger) and his 
group aimed to increase the knowledge about S. haematobium infection and its 
relationship with reproductive health in a community of women living in a hyper-
endemic village. The study included randomly selected females who had lived more 
than 1 year in the village. Women were invited to participate, provided they were not 
menstruating, not virgins, and were a minimum of 2 months post partum. Women were 
interviewed, underwent a gynaecological speculum investigation, and urinary 
examinations. Direct and gram stained genital secretions were examined.  
 
The study population constituted  of 150 women of whom 80% were below the age of 
36 years. Swimming (83%) and washing (58%) were the two main water contact 
activities; 32% of the population had urinary S. haematobium infection. Dysuria 
decreased with age as did history of haematuria.  S. haematobium ova in urine was not 
associated with dysuria, lower pubic pain, pollakisuria, pelvic pain, menstrual disorders, 
leucorrhoea, vulval itch, vulval lesions (incl. polyps), history of abortion, labour 
complications, still birth, premature delivery, infertility, condylomatous tumours, vulval 
and vaginal inflammation, cervicitis, cervical polyps, or cervix bleeding. ‘Tumefaction’ 
of the cervix was significantly associated with urinary S. haematobium.  
 
Discussion: The term tumefaction was discussed. Dr. Garba explained this as increased 
size – swelling – of the cervix, not necessarily associated with signs of cervicitis and Dr. 
Randrianasolo confirmed this. Dr Kjetland asked if this could be measured. Dr Kaseba, 
gynaecologist from Zambia said that cervices are of many different sizes. It was then 
suggested that clinical registrations and questionnaires in the different groups should  be 
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standardised and sharpened so that the study results could be compared. This would also 
hold true for the sandy patches, the description of pain, the visual/colposcopic 
inspections, and palpatory findings. Furthermore, the association between symptoms 
and infection should be analysed for confounders. 
 
Dr C. E. Ramarokoto (Madagascar) from the Pasteur Institut in Madagascar reported 
that transabdominal ultrasonography has previously revealed echogenic foci and masses 
in women from S. haematobium endemic areas. In a community based study in 
Northern Madagascar, systematic examination of the genital tract was done with 
intravaginal and transabdominal probes. Interestingly by ultrasonography, cervix, 
vagina, the tubes and ovaries were not different in the schistosomiasis endemic and non-
endemic area. There was no difference in number of polyps, cysts, hyperechogenecity, 
hydrosalpinges or volumes of cervix or uterus. Evaluated by transvaginal ultrasound the 
female genitals did not change after praziquantel treatment in any of the two villages. 
 
Female Genital Schistosomiasis and HIV Transmission 
Blair Research, together with the University of Zimbabwe, Biomedical Research and 
Training Institute and University of Oslo conducted an extensive clinical and 
laboratory study in a population of rural women in Zimbabwe. Kjetland and co-authors 
found sandy patches in 46% of the women. The HIV prevalence was 29% and herpes 
simplex type- 2 (HSV-2) prevalence was 65%. Permanently resident women between 
the ages of 20 and 49 years who were sexually active, non-pregnant and non-
menopausal were included in a cross-sectional study, with a one-year follow-up. HIV 
was found in 41% (29/ 70) of women with laboratory proven genital schistosomiasis as 
opposed to 26% HIV positive (96/375) in the schistosomal ova negative group. In 
multivariate analysis S. haematobium infection of the genital mucosa was significantly 
associated with HIV seropositivity (adjusted OR 2.9, 95%CI 1.11- 7.5, p=0.030). All 7 
women who became HIV positive in the study period (seroincidence 3.1%) had signs 
of S. haematobium at baseline. In accordance with other studies HIV was significantly 
associated with HSV-2 (OR 3.0, 95%CI 1.7- 5.3, p<0.001), syphilis and human 
papillomavirus. The highest HIV prevalence (45%) was found in the 25-29 years age 
group. There is some supporting evidence that can be drawn from other studies, which 
have demonstrated a higher level of HIV receptors CCR5 and CXCR4 in peripheral 
blood in S. mansoni infected individuals and more HIV receptors in genital lesions 
than in healthy tissue nearby. Furthermore, the sociological studies indicate that city 
prostitutes are often from rural areas, and in rural areas the HIV prevalence may be 6 
times higher in young women than in young men.  
 
Discussion: With the presence of chronic lesions one may suggest that the risk of 
getting HIV should maybe have been even higher. Women with genital 
schistosomiasis were found to have an almost 3-fold risk of having HIV. Other factors 
such as lifetime partners, dyspareunia and demographic data should be explored in 
more details. It was asked whether genital schistosomiasis is a progression of urinary 
schistosomiasis. In the ensuing discussion it was thought that the urinary and genital 
tracts were probably affected simultaneously through the venous anastomoses around 
the pelvic organs.  
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Dr P. Jourdan (Norway) quoted reports that have found genital ulcer disease and 
cervicitis to recruit immunologically active cells. Immune activation may increase both 
the number of target cells in the area and the number of chemokine receptors on each 
cell. Mononuclear cells from people with schistosomiasis are more susceptible to HIV 
infection in vitro than cells from people without schistosomiasis. This phenomenon has 
not yet been explored in genital cells from persons with schistosomiasis. Clinically, 
genital schistosomiasis is associated with abnormal blood vessels and mucosal bleeding. 
Studies have postulated that products secreted by S. mansoni ova may promote 
angiogenesis, similar to what is observed during the development of malignant tumours. 
This has led to the hypothesis that abnormal cells, receptors and blood vessels in genital 
schistosomal infection facilitate HIV transmission. This could be explored by further 
examination of biopsies taken from the female genital tract in relation to studies on FGS 
and the results may shed more light on the basis of increased susceptibility to HIV 
infection among women with genital schistosomiasis.  
 
Discussion: Dr. Vennervald suggested that the analyses could also be done in other 
types of biopsies, which are more readily available, such as biopsies from the urinary 
bladder from European patients with urinary schistosomiasis. These biopsies are often 
taken routinely if the patient presents with urinary lesions.  
 
Treatment of Female Genital Schistosomiasis 
Based on the current knowledge Dr. Kjetland set out to answer if treatment of female 
genital schistosomiasis belongs in an STI clinic. Syndromic management of the STIs, 
based on concepts of aetiology and local knowledge of the efficiency of therapy, are 
strategies in STI and HIV prevention. In the syndromic approach treat index person and 
partners are treated for bacterial discharge or genital ulcers. According to a number of 
reports this is controversial. Furthermore, diseases that are not treated such as herpes 
simplex will recur. This may create marital discord among couples and also distrust 
among people in the performance of the clinics. Moreover, unnecessary treatment is 
costly for already strained economies. However, where diagnostic tools and transport 
are scarce treatment is given based on proven effect on the clinical entity. 
 
Dr. Kjetland presented two sets of results from the 20-49 year-old women, who 
participated in the study from Zimbabwe.  
 
Briefly, treatment was provided at baseline (40mg/kg) and (60mg/kg) at 3 months. 
Multivariate analyses were run controlling for HIV status, age, timing of treatment 
(early to late in the transmission season) and the sexually transmitted diseases. 
Praziquantel did not have a significant effect on sandy patches, mucosal bleeding, or 
neovascularisation. Furthermore some women were seen after 2 and 5 years. Their 
genital lesions remained unchanged. Urinary schistosomiasis ova excretion, however, 
ceased. 
 
Women in the same cohort were asked about treatment prior to the study. Frequency of 
mucosal bleeding and sandy patches was significantly lower in women who had 
received treatment below the age of 20, even after correcting for current regular water 
contact and age. The different drugs used against S. haematobium seemed to have 
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different effect on the presence of genital morbidity. Lucanthonen hydrochloride (used 
before 1973), metrifonate (used app 1974-1995) and lastly praziquantel had, in this 
order, decreasing ‘protective effect’ against genital schistosomal morbidity. However, 
when adjusting for patient age at treatment, no difference was seen.  In conclusion, 
female genital lesions could possibly be prevented by early treatment. However, once 
established as chronic morbidity, there seem to be no demonstrable effect of treatment 
and the lesions remain unchanged.  
 
Dr Randrianasolo reported from the Madagascan study where, as previously mentioned, 
praziquantel treatment was delayed for one month whilst women were treated for STIs. 
Symptoms were recorded at baseline (before any treatment), 1 month (after treatment of 
STIs only) and at 6 months (after treatment with praziquantel). Five months after 
treatment with praziquantel there was no longer difference in urinary S. haematobium 
(or STI) prevalences in the two villages. Furthermore, symptom levels were now the 
same in the two villages. Although many women had no symptoms Dr Randrianasolo 
suggested that genital S. haematobium infection and STIs may have two symptoms in 
common: dyspareunia (not significant) and dysuria (significant). She suggested that 
pelvic discomfort and gross haematuria were symptoms of genital schistosomiasis and 
that praziquantel should be added to the existing anti-STI regimen in young women 
(aged 15-24) living in schistosomiasis endemic areas.  
 
Discussion: Although lesions did not change after treatment in the Zimbabwean women, 
the women from the schistosomiasis endemic village in Madagascar benefited from the 
praziquantel treatment with respect to some of the symptoms. CAA analyses had also 
been done and showed a significant reduction after treatment. Dr. Kjetland drew 
attention to the fact that the effect of praziquantel was the same in HIV positive and 
negative individuals, and also that urinary ova excretion had gone down satisfactorily. 
Dr. Sacko (Mali) suggested that treatment may work differently in the different 
populations and that schistosomiasis may manifest itself differently in different 
populations. Anti-schistosomal treatment must be considered in adult men from S. 
haematobium endemic areas, who attend the STI clinic or other clinical settings with 
uro-genital complaints. However, the efficacy of praziquantel treatment on lesions in 
the female genital tract must still be determined. In a clinical setting it may however be 
worthwhile to try praziquantel for unresolved genital complaints, especially if the 
patient is young or has only recently had her ‘schistosomal waterbody debut’. More 
research is needed on the effect of other treatment regimens on symptoms and lesions in 
the young and adult females.  
 
Male Genital Schistosomiasis Clinical Findings and Symptoms 
Dr P. Leutscher presented data on uro-genital symptoms reported by men living in an 
area of Madagascar where S. haematobium and STIs co-exist. Urethral discharge was 
significantly more frequently reported in the STI positive men compared to the STI 
negative men. Urethral discharge and/or dysuria were reported with different 
frequencies according to the different microorganisms: N. gonorrhoeae (75%), C.  
trachomatis (40%), M. genitalium (20%) and T.  vaginalis (25%). Half of the men 
tested positive for an STI or for S. haematobium were asymptomatic. Dysuria and 
painful ejaculation, in addition to gross haematuria, were associated to positive S. 
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haematobium infection status.  In men with moderate to high intensity of infection (≥ 50 
eggs/10 ml urine), gross haematuria and uro-genital discomfort were reported 
significantly more frequently than in men with low intensity of infection (1-49 eggs/10 
ml urine). 
 
Dr Leutscher also presented data on semen analysis in a cohort of 27 S. haematobium 
infected men. The mean apoptotic rate at baseline was 6.8%, which is abnormally high 
compared to reports from other cross-sectional studies. Fifteen (56%) individuals were 
detected with ova in semen. Apoptotic rate was significantly correlated to seminal ECP 
level. At follow-up, the prevalence and intensity of egg excretion in urine and in semen 
declined significantly in conjunction with a significant reduction in mean apoptotic rate 
to 3.3%. The study demonstrated that the spermatogenic cells in S. haematobium 
infected men undergo apoptosis, which seems responsive to anti-Schistosoma treatment. 
Egg induced inflammation in the seminal vesicles could be an underlying mechanism.  
 
In a Malagasy study population Dr C. E. Ramarokoto investigated men by transrectal 
and transscrotal probes. In males, hyperechogenic and calcified lesions have been 
demonstrated in the prostate and in the seminal vesicles concomitant with seminal egg 
excretion in non-immune male individuals infected during temporary stay in endemic 
areas. Men in this schistosomiasis endemic area had significantly more prostate 
hyperechogenecity and calcifications, and the seminal vesicles were significantly larger. 
Epididyma and hydrocele were equally prevalent in the two populations. In the 
schistosomiasis endemic village seminal vesicle hyperechogenicity and size decreased 
after treatment. The same was the case with prostate hyperechogenicity  whereas 
calcifications remained.  
 
Discussion: Symptoms of genital schistosomiasis have not been included in the DALY 
calculations for schistosomiasis. Some have reported pain on ejaculation and erection 
and alleviation of this after treatment to the extend that wives have come to ask for 
treatment for their husbands. In the light of these findings the burden of disease should 
be recalculated.  
 
Male Genital Schistosomiasis and HIV Transmission 
Dr Leutscher reported the findings from a study investigating the seminal inflammatory 
response to egg-infestation of the urogenital organs in 240 ejaculate donating men aged 
15 to 49 years living in a Schistosoma haematobium endemic area of Madagascar. In 29 
(12%) subjects detected with ≥5 ova excretion in the ejaculate, leucocytospermia, 
seminal lymphocytes and eosinophil leucocytes, were each significantly more prevalent 
compared that in 74 (31%) S. haematobium negative subjects (p<.01). In addition, 
seminal levels of interleukin IL-4, IL-6, IL-10 and tumor necrosis factor were 
significantly higher among seminal egg excreting subjects than among negative subjects 
(p<.001). Sexually transmitted infections did not act as confounders for the observed 
associations. At six months follow-up after systematic anti-schistosomiasis and STI 
syndrome treatment at baseline, the prevalence of seminal leucocytes decreased 
significantly amongst the previously seminal egg positive subjects. The same tendency 
was observed for the post-treatment levels of cytokines. Numerous studies have already 
shown an association between STI associated genital inflammation and HIV 
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propagation. Therefore, this study suggests that male urogenital schistosomiasis may 
constitute a risk factor for HIV transmission due to the egg-induced inflammation in the 
semen-producing pelvic organs. 
 
Discussion: Epidemiological and clinical studies are needed to investigate into the 
hypothesized relationship between male genital schistosomiasis and increased risk of 
HIV transmission. A pilot study is currently taking place in Malawi by Dr. Risa 
Hoffman from UCLA University as principal investigator aiming to measure HIV viral 
load in semen from S. haematobium and HIV co-infected men before and after 
treatment.  
 
Genital Schistosomiasis and Infertility 
Dr A. Keita (Mali) presented a case of secondary infertility in a patient with urinary 
schistosomiasis from an irrigation area in Mali. The woman was found to have bladder 
calcifications. Hysterosalpingography revealed bilateral obstructions of the Fallopian 
tubes. Dr Keita suggested that community based research should be done on the 
association between urinary schistosomiasis and infertility and bladder cancer. He also 
suggested that the association between genital schistosomiasis and lymphatic filariasis 
should be explored as well.  
 
Discussion: Dr Kjetland pointed out that there are many reports of concomitant findings 
of female infertility and genital schistosomiasis. S. haematobium is rarely found in the 
uterus. There are a few case reports of stunting and late pubertal development confirmed 
in animal models with decreased fertility and arrested development of corpora lutea. 
This may indicate that there may be hormonal disturbances in women with 
schistosomiasis. Furthermore, there are many case reports on tubal schistosomiasis and 
ectopic pregnancies. The Zimbabwean study did not find a higher rate of abortions or 
complicated pregnancies in women with genital schistosomiasis, but was not designed 
to detect the effect of S. haematobium on these fairly rare phenomena. Some case 
reports suggest that anti-schistosomal treatment has resulted in pregnancy. However, all 
previous analyses lack information about other diseases that may cause tubal 
obstruction. Although the Zimbabwean study has found some association with 
secondary infertility no study has yet been large enough to control for STIs. It would be 
very natural to assume that if S. haematobium causes secondary infertility it would also 
cause increased prevalence of primary infertility and sub-fecundity. Furthermore, the 
effect of S. haematobium infection on male infertility has not been explored. Male S. 
haematobium caused infertility could be a confounder in the analyses of effect of S. 
haematobium on female fertility.  
 
Diagnosis of Genital Schistosomiasis 
The clinical diagnosis of female genital schistosomiasis is currently dependent on a 
good light source or even a colposcope. The crushed biopsy of genital tissue is still 
considered the gold standard for the parasitological diagnosis of genital S. haematobium 
infection. However, the ova are located in highly focal clusters and one may miss them, 
especially with histological sectioning of a biopsy. Moreover, women in parts of the 
schistosomiasis and HIV endemic areas might neither have a choice of whether to have 
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intercourse or not nor the courage to suggest use of a barrier contraceptive method. 
Hence, taking a biopsy for the diagnosis of genital S. haematobium remains an HIV 
transmission risk for the patient and her partner until the inflicted wound has healed, 
and biopsies are thus not acceptable in these settings and are raising ethical concern. 
Wet smears and PAP smears may contribute to the diagnosis but the sensitivity is low.  
 
University of Leiden has developed PCR in faeces and/or urine for a number of 
intestinal parasites and for urinary schistosomiasis. Robert ten Hove presented a brief 
list of possibilities for PCR analysis on faecal samples before he presented an example 
of using PCR as a tool for diagnosing schistosomiasis. The Assay 1 Real time PCR 
targets the S. mansoni (label FAM), S. haematobium (NED-MGB) cytochrome c 
oxidase subunit 1 and Assay 2 targets the schistosoma genus (label FAM) on rDNA 
repeat ITS2. Assays have been run on specimens from Northern Senegal consisting of 
176 ethanol suspended stool samples stored at room temperature, There was a 
significant correlation between S. mansoni Kato Katz findings and PCR, i.e. the median 
PCR value was significantly correlated with egg count (Kappa 0.44, p<0.01). In a few 
urine samples from Gabon decreasing PCR values were observed with increasing 
intensity of infection. This was particularly obvious for specimens that had been stored 
at minus 80 C. Furthermore, stool samples stored at room temperature in ethanol 
seemed to provide a good correlation with the presence of urinary S. haematobium. The 
PCR analyses are expensive, but could hypothetically replace rural gynaecological 
investigation. In the field the samples for analysis could be obtained in a much simpler 
way. Furthermore, a single sample could potentially be used to diagnose all the STIs in 
a multiplex PRC approach.  
 
Discussion: This test could probably be used on vaginal lavage specimens as well as on 
male genital specimens. Concerning specimens from male genitals the risk of 
contamination with urine and thereby eggs in urine was emphasised. For the same 
reason, it was stressed that in females it is important that the specimen is taken ‘deep 
enough’.  
 
Urinary Schistosomiasis and HIV 
Dr P. Ndhlovu reported on a multidisciplinary study conducted in rural Zimbabwe 
where 722 women registered for the study, 557 fulfilled the inclusion criteria and HIV 
status was determined in 544. Geometric mean egg count in those who had urinary 
schistosomiasis was 5.1 eggs/10ml urine. S. haematobium prevalence was highest in the 
youngest age (60%) group and declined to 29% in older individuals (p<0.001). Intensity 
of infection followed the same pattern. HIV prevalence was 20% in those below the age 
of 20 and peaked in the 25-29 year olds (44.4%) after which it declined to 17.1% in 
those above the age of 45. Women from the Shona tribe with urinary schistosomiasis 
had significantly more HIV than those without schistosomiasis (p=0.02). Women above 
the age of 35 years and infected with urinary schistosomiasis were more than twice as 
likely to be HIV positive than those who were urinary schistosomiasis negative. 
 
The granulomatous inflammatory response induced by trapped schistosome eggs is 
responsible for manifestations of schistosomiasis. The major effector mechanism is an 
antibody-dependent cell-mediated cytotoxic reaction where CD4 positive cells are 
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active. The Th2 cytokine responses dominate in schistosomal infection while an optimal 
resistance to HIV is a predominantly Th1 response. Furthermore it has been 
hypothesized that the cells constituting the Schistosoma egg granuloma may contain 
specific receptors for HIV. Helminth infections in general suppress IL-2 and it has been 
hypothesized that this may increase the susceptibility to HIV transmission and 
propagation.  
 
Dr Ndhlovu suggested that treatment and control of schistosomiasis may be an 
important complementary method to control the HIV pandemic in rural African 
populations. Future studies should include more than one method of schistosomiasis 
diagnosis, information about the time of HIV seroconversion and CD4 cell counts. 
Furthermore, differences in water contact patterns may confound the analysis of the 
association between HIV and schistosomiasis. Dr Ndhlovu suggested that further 
research is needed to explore new treatment strategies that will target the genital lesions 
in adults.  
 
Discussion: The differences among the tribes were discussed. Dr Ndhlovu emphasised 
that a number of factors were not explored in this study and the lack of association 
between urinary schistosomiasis and HIV among the other tribes could be due to 
differences in duration of exposure to schistosomiasis. 
 
Urinary and Genital Schistosomiasis Relations  
Dr Kjetland reported that among women with urinary schistosomiasis in the different 
studies up to 65% also have schistosomiasis in the genitals and based on this one may 
ask if it is really necessary to do gynaecological investigations. In the Zimbabwean 
female genital study the mean intensity of urinary schistosomiasis infection was 
significantly higher in women with genital schistosomiasis (p=0.05). However 41% of 
the women without ova in urine had genital schistosomiasis. Furthermore, in the 
Zimbabwean study 123 of the 234 cases of genital schistosomiasis (53%) would not 
have been identified as Schistosoma  egg positive without the genital inspection.  
 
Schistosomiasis in HIV Positives 
Dr V. Mwanakasale presented results from a study conducted among individuals aged 
10-55 year in the copper belt of Zambia. They had found that the prevalence of heavy 
infections were lower in individuals with HIV and likewise, the proportion of 
haematuria. They only included people who had no signs or symptoms of HIV, and 
CD4 counts and viral load determinations were not done. Dr. Mwanakasale suggested 
that urine samples may be false negative for S. haematobium in HIV endemic areas and 
that a more sensitive technique for diagnosis is needed.  
 
Discussion: It was asked if haematuria was quantified and compared in HIV positive 
and negative, but this information was not available. Similar to all the other genital 
schistosomiasis studies there was little information on the sociodemographic status. It 
was thus argued that HIV positive individuals may be from another segment of the 
population than HIV negatives. In the ensuing discussion it was contested that better 
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diagnostic methods are needed as other studies have found ample schistosomiasis in the 
HIV positive.  
 
Dr P. Kallestrup presented the MUSH-study, also from rural Zimbabwe. The study 
aimed to compare the intensity of schistosomiasis infections in HIV negative, HIV 
positive, and HIV immunodeficient individuals. Furthermore, the efficacy of 
praziquantel in immunocompromised HIV positive individuals was determined and the 
study sought to explore the effect of treatment on the course of HIV infection in HIV 
and schistosomiasis co-infected individuals.  
 
Contrary to findings in Kenya and Zambia the Zimbabwean study revealed no 
difference of egg excretion in HIV positive and negative individuals. The egg excretion 
decreased satisfactorily after treatment but levels of the circulating schistosome antigen, 
CAA, declined to a lesser extend in HIV positive individuals. The study in Zimbabwe 
was considerably larger than the other studies from Kenya and Zambia, but the intensity 
of S. haematobium was lower.  
 
CD4 counts were lower in HIV negative patients with S. mansoni than in those without 
S. mansoni. In this rural Zimbabwean study untreated schistosomiasis was associated 
with a minor increase in viral load, while treatment arrested this increase. This was 
contrary to a small study in Kenya and a larger study in Uganda showing increased viral 
loads among the individuals who were treated. However, there were some differences 
among the studies. The Zimbabwean study was a randomised controlled study in an 
area with primarily S. haematobium infections of relatively low intensity whereas the 
Uganda study was primarily S. mansoni with higher intensities 
 
Discussion: The main messages from this study were that egg counts can be used to 
diagnose schistosomiasis in HIV positive individuals and that praziquantel treatment is 
efficient in HIV positive patients. Although this was a randomised study it would have 
been an advantage to know more about the individuals who dropped out of the study 
and to have information about TB, episodes of clinical malaria and sociodemographic 
data. Dr Kjetland commented that the reported effects on viral loads were clinically 
insignificant and had been assessed over very short periods. The current findings 
regarding the difference in viral load would be of no clinical significance or relevance. 
Dr Kallestrup confirmed that HIV experts had stated this previously. Dr Kallestrup 
would like to see schistosomiasis research as a component in ART studies. Moreover, 
Dr Gundersen suggested that follow-up studies based on several of the presented studies 
would be interesting.  
 
Future Prospects 
Dr M. Chimbari pointed out that the pending climate change may affect schistosomiasis 
transmission. Even though Africa has contributed the least to these changes it is likely 
to be affected the worst. There will be varying precipitation as Southern Africa is likely 
to become hotter and drier whilst central Africa will become hotter and wetter. 
Furthermore, Dr Chimbari showed that the number of so-called extreme events 
(droughts, floods, cyclones) is higher in the developed countries but that the death tolls 
are highest in Africa.  
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The climate change may increase the temperature in higher altitudes, change human 
settlement patterns and affect the movement of people. It may also affect the number of 
vectors such as mosquitoes and snails by increasing the number of breeding sites. 
Between 1982 and 1996 the prevalence of S. haematobium increased in Matabeleland 
from 14.3 to 30% and S. mansoni was transmitted in areas where it had been absent in 
the 1982 survey. It has thus been hypothesized that malaria and schistosomiasis 
transmission will increase.  
 
In order to intervene, there should be monitoring, early warning, forecasting, public 
education, and support for infectious diseases control. This is particularly challenging in 
African countries that have poor infrastructure, no funds dedicated for emergencies, low 
literacy rates in some areas, poor surveillance systems, armed struggles and government 
disagreements. Dr Chimbari listed possible funding opportunities on the subject of 
climate change: Global Environmental Facility (GEF) Trust Fund; Special Climate 
Change Fund (SCCF); Least Developed Countries Fund (LDCF); Kyoto Protocol 
Climate Adaptation Fund; IDRC funded Climate Change Adaptation in Africa (CCAA); 
WaterNet; Water Research Fund for Southern Africa (WARFSA); African Technology 
Policy Systems (ATPS).  
 
Dr L. Mubila (Afro-WHO) presented the WHO strategic objective to reduce morbidity 
of schistosomiasis by prevention and regular treatment. At present WHO recommends 
two indicators for schistosomal morbidity – namely gross haematuria and ultrasound 
detectable changes in affected organs. WHO recommends management of cases and 
regular treatment of school aged children and other high-risk groups. Women of child-
bearing age have been defined as a high-risk group along with occupational groups such 
as fishermen. Intersectorial collaboration is recommended including education, water 
and sanitation, as well as ensuring that developmental activity that may cause further 
spread of parasitic diseases must be accompanied by preventive measures. Dr. Mubila 
suggested that management of genital schistosomiasis should be integrated in the 
preventive measures for school aged children, in STI management programmes and/or 
in HIV/AIDS information packages. 
 
The Way Forward 
Dr P. S. Mbabazi (WHO, Geneva) gave an overview of WHO priorities and presented 
some questions. Neglected tropical diseases are known to have low fatality rates but 
high morbidity, and they are signs of systemic and systematic disadvantage. To a large 
degree the neglected diseases affect rural and remote populations, cause social 
stigmatisation and low-cost, effective public health tools are available. Furthermore, 
there may be paucity of data and minimal development of new tools and treatment.  
 
WHO is dependent on data flow from the village levels to national and regional levels 
and also to WHO. It is a programmatic priority to combat disease by implementation of 
preventive chemotherapy and to monitor and evaluate adverse events, drug coverage, 
and efficacy. Halted chemotherapy before the parasite has been eliminated may render 
drugs ineffective, and both treatment and vector control are recommended strategies.  
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Dr Mbabasi stated that there is scanty information on management of adolescent illness 
as well as of co-morbidity and co-infections (e.g. schistosomiasis and HIV). Dr Mbabasi 
presented some questions from WHO:  
1. The HIV-schistosomiasis relationship should be quantified and characterised  
2. Global, regional, national data: what are the prevalence rates and disease burden 
data for schistosomiasis in HIV positive individuals and pregnant women? 
3. The impact of treatment given to pregnant women should be quantified. Are 
there any associated benefits? 
4. Does preventive chemotherapy (PCT) prevent HIV transmission? Can we 
enhance protection of populations with PCT? (given a focused implementation 
of school-based programmes – largely not childbearing, not sexually active): 
what is the evidence to further PCT? 
5. Are current activities interfacing with the WHO-HIV department? If so, how?  
6. If any, what is the current interface with national programmes?  
7. How would current HIV-schistosomiasis activities fit into existing systems? 
8. WHO needs to know what research is planned, including operational research to 
obtain further evidence 
9. For global advocacy: It is necessary to develop a clear, strong message 
 
WHO is setting up a register for pregnant women treated with ACTs and anti-
helminthic drugs. It is implemented in many African countries already. With expanded 
access to treatment there is an increasing need to assess risks associated with exposure 
to drugs both for mother and child.  
 
Mr M. P. Mapingure asked the question of what is fuelling the HIV epidemic in 
different populations. For example why are young women more susceptible to infection 
than men? Or why is the Tanzanian epidemic not as severe as the Zimbabwean? Mr. 
Mapingure went on to list factors that may influence the HIV epidemic, such as STIs, 
number of sexual partners, male circumcision, male viral load, HIV background 
prevalence. There may be an association between genital schistosomiasis and HIV. This 
relationship will be affected by the duration of the lesion.  
 
He went on to present examples of e.g. mother to child transmission. There is now 
mathematical software that has been fitted to data collected from many studies. 
Attributable fractions of new HIV cases due to HSV-2 (and other STIs) have been 
calculated for different time periods. Mr. Mapingure wished to explore the role of both 
schistosomiasis and STIs in the current and past incidence and prevalence of HIV 
incidence and prevalence and thereby try to find an explanation for the differences in 
HIV prevalence in Tanzania (6.9%) and in Zimbabwe (25.6%).  
 
Prof M. Taylor presented a study planned to take place in KwaZulu-Natal. It is designed 
as a prospective study in schoolgirls treated yearly, as recommended by WHO, and with 
several cross-sectional gynaecological surveys in sexually active young adult women. 
The hypothesis is that early treatment may prevent both HIV transmission and chronic 
genital lesions and the study will provide data on the effect of praziquantel on genital 
lesions and on a potential protective effect on HIV transmission.  
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Discussion: It is important to collect information about prior treatment, especially 
among the controls. 
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ANNEX 1 
 
Workshop 
Schistosomiasis and Reproductive Health 
22-25 January 2008, Lusaka, Zambia 
 
Tuesday 22 January 
Time  Speaker Chair 
8.30 – 9.00  Registration   
9.00 – 10.00 Delegates and invited guests arrive and are seated 
 
Arrival of Guest of Honour – Hon Dr B. Chituwo, 
Minister of Health, Zambia 
 
National Anthem 
 
Welcome remarks and speech from DBL 
representative 
 
Permanent Secretary, Ministry of Health calls upon 
the Hon. Minister of Health 
 
Speech by the Hon. Minister of Health 
 
Close of Opening Ceremony 
 
 
 
 
 
 
 
Dr N. Oernbjerg, 
Director of DBL 
 
Dr S.K Miti 
 
 
Hon. Dr B. 
Chituwo 
 
Dr J. 
Mwansa 
10.00 – 10.30 BREAK   
FGS in an HIV era – an introduction 
10.30 – 10.50 Social aspects of genital schistosomiasis in women 
 
No. 1 
H.A. Farook 
 
11.00 – 11.20 The HIV epidemic in Zambia 
 
No. 2 
M. Muteteka 
 
11.30 – 11.50 Insights into modelling techniques for 
schistosomiasis and sexually transmitted infections 
No. 3 
M. P. Mapingure 
J. Mwansa 
& P. 
Kallestrup 
12.00 – 13.00 LUNCH   
Clinical aspects of genital schistosomiasis – findings from the field 
13.00 – 13.20 Clinical findings of female genital schistosomiasis 
after controlling for confounders. Is urinary 
schistosomiasis a useful indicator? 
 
No. 4 
E. F. Kjetland 
 
13.30 – 13.50 Male genital schistosomiasis: Symptoms and semen 
analysis 
No. 5 
P.D. Leutscher 
 
14.00 – 14.20 Clinical, parasitological and ultrasound study of 
female genital Schistosomiasis, due to Schistosoma 
haematobium infection in an endemic Nigerian 
village, in 2005.  
No. 6 
A. Garba 
 
 
 
15.00 – 15.30 BREAK   
15.30 – 15.50 Uro-genital schistosomiasis in rural Madagascar: No. 7  
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Ultrasonographical findings  
 
C.E. Ramarokoto 
 
16.00 – 16.30 Summary and general discussion 
 
Chair 
19.00 DINNER   
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Wednesday 23 January 
Time Topic Speaker Chair 
HIV transmission in schistosomiasis endemic areas 
9.00 – 9.20 Schistosomiasis and HIV in Zimbabwe – the MUSH 
study  
 
No. 8 
P. Kallestrup 
 
9.30 – 9.50  Urinary schistosomiasis and HIV 
 
No. 9 
P.D. Ndhlovu 
 
10.00 – 10.30 BREAK  
10.30 – 10.50 Male genital schistosomiasis and HIV 
 
No. 10 
P.D. Leutscher 
 
11.00 – 11.20 Genital schistosomiasis association with HIV 
 
No. 11 
E.F. Kjetland 
 
11.30 – 11.50 Female genital schistosomiasis in Madagascar: 
Symptoms and pelvic examination 
No. 12 
B. Randrianasolo 
 
12.00 – 13.00 LUNCH  
13.00 – 13.20 Viral load in blood after treatment – repercussions 
for the HIV epidemic with genital schistosomiasis in 
mind  
No. 8 
P. Kallestrup 
 
13.30 –13.50 Diagnosing urinary and intestinal schistosomiasis in 
the HIV area, a review of the literature  
No. 13 
V. Mwanakasale 
 
14.00 – 14.20 The effect of S. haematobium ova on mucosal blood 
vessels and cells with special attention to 
susceptibility to HIV transmission.  
An immunohistochemical and histopathological 
study.  
No. 14 
P.M. Jourdan 
 
 
14.30 – 15.00 Summary and general discussion 
 
Chair 
A. Garba &  
R. ten Hove 
15.00 – 15.30 BREAK   
Treatment and control of genital schistosomiasis 
15.30 – 15.50 Treatment of genital schistosomiasis, does it belong 
in a STD clinic? 
 
No. 20 
E.F. Kjetland 
 
16.00 – 16.20 WHO preventive chemotherapy strategy for control 
of Schistosomiasis in integration with other neglected 
tropical diseases. 
 
No. 21 
L. Mubila 
16.30 – 16.40 General discussion on treatment and control of 
genital schistosomiasis  
 
Chair 
N. Midzi &  
P. Leutscher 
19.00 DINNER   
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Thursday 24 January 
Time Diagnosis of genital schistosomiasis Speaker Chair 
9.00 – 9.20  The clinical and bedside investigations – 
unfeasible, uncomfortable, imprecise, 
dangerous and futile? 
No. 15 
E.F. Kjetland 
 
9.30 – 9.40 ECP in female genital schistosomiasis, a 
useful analysis in some cases? 
No. 16 
N. Midzi 
 
9.50 – 10.00 The relationship between IgA or neopterin 
in vaginal fluids, genital smears and urine. 
Implications for field use.  
No. 17 
T. Mduluza 
 
 
10.00 – 10.30 BREAK  
B. 
Randrianasolo 
& B. 
Vennervald 
   
10.30 – 10.50 PCR for schistosomiasis in faeces. The 
technical approach to doing the same in 
vaginal lavage or genital smears 
  
No. 18 
R. ten Hove 
11.00 – 11.20 Eosinophil cationic protein (ECP), soluble 
egg antigen (SEA), and circulating anodic 
antigen (CAA) in male genital 
schistosomiasis 
 
No. 19 
P.D. Leutscher 
11.30 – 12.00 Summary and general discussion 
 
Chair 
 B. 
Randrianasolo 
&  
B.Vennervald 
12.00 – 13.00 LUNCH   
 
Excursion 
Visit to Primary School (Kamulanga)  
Schistosomiasis, Soil transmitted Helminths and HIV/AIDS control programme activities  
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Friday 25 January 
Time Topic Speaker Chair 
 Ongoing and upcoming research   
9.00 – 9.20 Schistosomiasis in young women and girls 
in KwaZulu Natal  
 
No. 22 
M. Taylor 
 
9.20 – 9.40 Male genital schistosomiasis as risk factor 
of HIV transmission – a study from Malawi 
 
No. 23 
R. Hoffmann 
09.40 – 10.00  Climate changes and tropical diseases 
 
No. 24 
M. Chimbari 
 
10.00 – 10.20  WHO priorities and the work of setting up 
a register for pregnant women treated with 
ACTs and antihelminths  
 
P. Mbabazi 
R. Banda & 
P. Leutscher 
10.30 – 11.00 BREAK   
Research Priorities 
11.00 – 11.20 Genital schistosomiasis diagnosis and 
treatment 
 
Gaps in knowledge and research priorities 
Chair from the 
session on 
diagnosis of 
genital 
schistosomiasis 
11.30 – 11.50 HIV and schistosomiasis 
 
Gaps in knowledge and research priorities  
Chair from the 
session on HIV 
transmission in 
schistosomiasis 
endemic areas 
12.00 – 12.30 General discussion and comments  
 
Chair 
E.F. 
Kjetland & 
L. Mubila 
 
(Peter to 
assist with 
taking notes) 
12.30 – 13.00 Closing ceremony 
 
 
 
  
 LUNCH   
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ANNEX 2 
Workshop on 
Schistosomiasis and Reproductive Health 
Lusaka, Zambia 22-25 January 2008 
Participants 
# Name Contact information 
Cameroon 
1. Louis Albert Tchuem 
Tchuenté, Prof  
National Program for the Control of 
Schistosomiasis and STH 
Centre for Schistosomiasis and Parasitology 
P.O.Box 7244 
Yaoundé 
Cameroon 
Ph: +237 2221 0183 
Cell: +237 9991 1809 
Fax: +237 2 221 5077 
E-mail: 
tchuemtchuente@schisto.com 
 
Denmark 
2. Kirsten Grønlund 
Andersen, Ms 
 
DBL – Centre for International Health 
Research and Development 
Faculty of Life Sciences 
Thorvaldsensvej 57 
1871 Frederiksberg C 
Ph: +45 35 33 14 01 
Fax: +45 35 33 
E-mail: kga@life.ku.dk  
 
 
3. Helle Lohmann Scholer, 
Ms 
DBL – Centre for International Health 
Research and Development 
Faculty of Life Sciences 
Thorvaldsensvej 57 
1871 Frederiksberg C 
Ph: +45 35 33 14 11 
Fax: +45 35 33 14 33 
E-mail: hlsc@life.ku.dk  
 
 
 
4. Niels Ørnbjerg, Dr DBL – Centre for International Health 
Research and Development 
Faculty of Life Sciences 
Thorvaldsensvej 57 
1871 Frederiksberg C 
Ph: +45 35 33 20 14 
Fax: +45 35 33 14 33 
E-mail: no@life.ku.dk  
5. Birgitte Jyding 
Vennervald, Dr 
DBL – Centre for International Health 
Research and Development 
Faculty of Life Sciences 
Thorvaldsensvej 57 
1871 Frederiksberg C 
Ph:+45 35 33 14 40 
Fax: + 45 35 33 14 33 
E-mail: bjv@life.ku.dk 
6. Peter Leutscher, Dr 
 
 
Dept for Infectious Diseases 
Skejby Hospital 
Brendstrupgårdsvej 
8200 Aarhus N 
Denmark 
Ph: + 45 89 49 55 66 
Fax: 
E-mail: APD@sks.aaa.dk 
 
 
7. Per Kallestrup, Dr Department of infectious diseases 
Rigshospitalet 
University of Copenhagen 
Blegdamsvej 9 
2100 Copenhagen 
Denmark 
Mailing address: 
Skødstrup Lægepraksis 
Stationsvangen 70 
8541 Skødstrup 
Denmark 
Ph: +45 86 272424 
Fax: +45 86993588 
E-mail: kallestrup@dadlnet.dk 
 
Egypt 
8. Heba Farouk Ali, Dr 
 
65 Hightown Rd. 
Banbury 
Ph:+44 7725849910 
Fax: +441295229901 
 
 
30
 Oxfordshire 
Ox16 9BE 
E-mail: hebafali@yahoo.com 
 
Madagascar 
9. Charles Emile 
Ramarokoto, Dr 
Unite Epidemeio 
Institute Pasteur de Madagascar 
PO box 1274 Antananarivo 
Madagascar 
Ph: +261 20 22 412 72 
Cell: +261 32 04 538 59 
Fax: +261 20 415 34 
E-mail: charlesr@pasteur.mg 
10. Bodo Randrianasolo, Dr, 
Ms 
Unite epidemic 
Institute Pasteur de Madagascar 
P.O.Box 1274  
Antananarivo 
Madagascar 
Ph: +261 202267504 
Mobile: +261 32 07662 44 
Fax: +261 2022 67504 
E-mail: unc-bodo@moov.mg 
Malawi 
11. Exnevia Gomo, Dr 
 
Research support centre 
College of Medicine 
University of Malawi 
Private Bag 360 
Chichiri 
Blantyre 3 
Malawi 
Ph:+265 1880323 
Fax:265 1880182 
E-mail: egomo@rsc.medcol.mw 
exgomo@yahoo.com (PLEASE 
COPY ALL MAIL TO THIS 
ADDRESS) 
 
12. Peter Makaula, Dr Lake Malawi Schisto Control Programme 
P.O.Box 345 
Mangochi 
Malawi 
Ph: +265 8 850 829 
Fax: NA 
E-mail: chisale@malawi.net 
petmakau@yahoo.co.uk 
Mali 
13. Moussa Sacko, Dr 
 
Institute National de Recherche en Santé 
Publique  
B.P. 1771 
Bamako 
Mali 
Ph: +223 2239211 
Ph: +223 222 2028 
Fax: +223 221 4320 
E-mail: msacko@afribonemali.net 
14. Adama Diaman Keita, 
Dr 
Service de Radiologie et Imagerie Médicale 
Hôspital National du Point G 
BP 333,  
Bamako  
Mali 
Ph (cell): +223 646 06 05 
Fax: 
E-mail: gadkeita@yahoo.fr 
Niger 
15. Amadou Garba Djirmay, 
Dr 
RISEAL 
Programme de lutte contre les maladies 
tropicales négligées  
333, avenue des Zarmakoye 
B.P. 13724 
Niamey 
Niger 
Ph: +227 2075 2113 
Ph: +227 96590453 
Fax: +227 75 31 80 
E-mail: garbamadou@yahoo.fr 
 
pnlbg@intnet.ne 
The Netherlands 
16. Robert Jan ten Hove, Ir 
 
Department of Parasitology 
Albinusdreef 2 
PO Box 9600  
2333 ZA Leiden  
The Netherlands 
Ph: +31 71 526 5081 
Fax: +31 71 5266907 
E-mail: R.ten_hove@lumc.nl 
 
Norge 
17. Eyrun F. Kjetland, Dr  Centre for Imported & Tropical Diseases 
Department of Infectious Diseases 
Ullevaal University Hospital 
0407 Oslo 
Norway 
Ph: +47 2211 9101 /  
+47 9700 8579 
Fax: +47 2211 9181 
E-mail: e.f.kjetland@medisin.uio.no 
18. Svein Gunnar 
Gundersen, Prof 
Research unit, Sorlandet Hospital HF and 
University of Agder 
Ph: +47 90828335 
Fax: +47 38074173 
 
 
31
Kristiansand 
Norway 
 
Teglverksvn.14 
4632 Kristiansand 
Norway 
E-mail: svein.g.gundersen@sshf.no  
 
19. Peter Mark Jourdan, Dr Centre for Imported and Tropical Diseases 
Department of infectious Diseases 
Ullevål University Hospital 
0407 Oslo 
Norway 
Ph: +47 40242327 
Fax: + 47 22 11 91 81 
E-mail: pmjourdan@yahoo.no 
South Africa 
20. Myra Taylor, Prof Dept. of Public Health Medicine 
Nelson Mandela School of Medicine 
University of KwaZulu  Natal 
Private Bag 7 
Congella 4013 
Durban  
South Africa 
Ph: +27 31 2604499 
Fax: +27 31 260 4211 
E-mail: TAYLOR@ukzn.ac.za 
 
Switzerland 
21. Pamela Sabina Mbabazi, 
Dr 
Preventive Chemotherapy and Transmission 
Control 
Control of Neglected Tropical Diseases 
WHO 
20, Avenue Appia 
1211 Geneva 27 
Switzerland 
Ph: +41 22 791 4588 
Fax: +41 22 791 4777 
E-mail: mbabazip@who.int 
United Kingdom 
22. Patricia Doris Ndhlovu, 
Dr 
 
Metabolic and Clinical Trials Unit 
Camden Mews Day Hosptial 
5 Camden Mews 
London 
NW1 9DB 
United Kingdom 
Ph: +44 207 530 6936 
Fax: +44 207 530 6931 
E-mail: 
patricia.ndhlovu@candi.nhs.uk  
23. Fiona Fleming, Ms SCI, DIDE 
Room 312 
Old Medical School 
St. Mary’s Campus 
Imperial College London 
Norfolk Place 
London W2 1PG 
United Kingdom 
Ph: +44 (0) 20 759 43626 
Fax: +44 (0) 2072628140 
E-mail: f.fleming@imperial.ac.uk 
 
USA 
24. Julie Jacobson, Dr Bill and Melinda Gates Foundation 
PO Box 23350 
Seattle, WA 98102 
Ph: +(206) 709-3100 (Reception) 
Fax: 
E-mail: 
Julie.jacobson@gatesfoundation.org 
25. Risa Hoffman, Dr Division of Infectious Diseases 
UCLA Program in Global Health 
10833 Le Conte Ave 37-121 CHS 
Los Angeles, CA 90095 
USA 
Ph: (310) 825-7225 
Fax: (310) 825-3632 
E-mail: rhoffman@mednet.ucla.edu 
 
Zambia 
26. Victor  
Mwanakasale, Dr 
The Tropical Diseases Research Centre 
P.O.Box 71769 
Ndola  
Zambia 
Ph: +260 2 620 737 
Fax: +260 620 737 
E-mail: vicsale@zamtel.zm 
 
 
 
32
27. James Mwansa, Dr Zambia Bilharzia Control Programme 
C/O University Teaching Hospital 
Department of Pathology and Microbiology 
Private Bag R.W. 1X 
Lusaka 
Zambia 
Ph: +260 1 231361/256106 
Fax: +260 1256106 
E-mail: jclmwansa@yahoo.ca 
 
28. Njapau Samson, Mr Zambia Bilharzia Control Programme 
Ministry of Education 
P.O.Box 50092 
Haile Sailase Road 
Lusaka 
Zambia 
Ph: +260 211 25 4848 
Fax: + 
E-mail: samnjapau@yahoo.co.uk 
29. Christine Kaseba, Dr University Teaching Hospital 
Department of Obstetrics & Gynaecology 
Private Bag RW 1X 
Lusaka 
Zambia 
Ph: +260 1 253359 
Fax: +260 1 250 305 
E-mail: cmkaseba@yahoo.com 
30. Peter Songolo, Dr World Health Organisation 
UN Annex Building 
Plot 4609, Cnr Beit/Andrew Mwenya Roads 
P.O.Box 32346 
Lusaka 
Zambia 
Ph: +260 1 255322/336 
Fax: +260 1 252863 
E-mail: songolop@zm.afro.who.int 
Zimbabwe 
31.  Moses Chimbari, Prof 
 
Harry Oppenheimer Okavango Research 
Centre (HOORC) 
University of Botswana 
P. Bag 285, Maun 
Botswana 
Ph: +267 686 1833 
Cell: +263 91 252 754 
Fax: +267 686 1835 
E-mail:  
mjchimbari@gmail.com 
32. Likezo Mubila, Dr WHO ISTI ESA 
OTD Unit 
P.O.Box 773 BE, Belvedere 
Harare 
Zimbabwe 
Ph: +263 4 706 951 
Fax: +263 4 746 000 7011 Ext. 
381060 
E-mail: mubilal@zw.afro.who.int  
33. Takafira Mduluza, Dr  Department of Biochemistry 
University of Zimbabwe 
Box MP 167 
Mount Pleasant 
Harare 
Zimbabwe 
Ph: +263 4 334052/303813 
Fax: + 263 4 333 407 
E-mail: tmduluza@yahoo.com 
 
 
34. Nicholas Midzi, Dr National Institute of Health Research 
Box CY 573 
Causeway 
Harare  
Zimbabwe 
Ph: +263 4 700 457 
Fax: +263 4 253979 
E-mail: midzi@blair.co.zw 
nicholasmidzi@yahoo.com 
 
35. Munyaradzi Paul 
Mapingure, Dr 
University of Zimbabwe 
P.O.Box MP 167 
Mount Pleasant 
Harare 
Zimbabwe 
Ph: +263 2 333 6998 
Fax: +263 4 308 046 
E-mail: 
mmapingure@science.uz.ac.zw 
mapingurem@hsc.pg wits.ac.za 
pmapingure@yahoo.co.uk 
 
 
 
33
ANNEX 3 
Abstracts 
 
ABSTRACT No. 1
 
Social aspects of genital schistosomiasis in women 
 
Heba Farook Ali, Dr1 
 
1 65 Hightown Rd., Banbury, Oxfordshire, Ox16 9BE, UK 
 
Female Genital Schistosomiasis (FGS) is a disease entity characterized by considerable 
individual and public health hazards. It is detected by the presence of eggs of S.haematobium in 
the upper or lower reproductive tract of women. It has been reported to lead to a group of 
morbidity conditions such as infertility, complications of pregnancy such as stillbirth, abortion 
and miscarriages, menstrual disorders, problems related to sexual intercourse, unspecified 
complaints related to blood loss, chronic abdominal pain, in addition to social segregation and 
related psychological problems.  
Despite this, it remains a neglected disease entity and no reliable data exists on its prevalence 
and the true extent of the morbidity it causes. 
 
The study aimed to explore the occurrence of  FGS in a small rural population. As well as 
estimate the extent of  reproductive morbidity among the women studied. A small village was 
selected in Fayoum Governorate in Egypt. All eligible women were interviewed and underwent 
a clinical and gynecological examination had a cervical smear and biopsy taken, in addition, a 
routine urine examination and blood analysis was done. 
 
FGS was discovered among 50% of the women in the study. In addition, a high prevalence of 
other reproductive tract morbidities such as reproductive tract infections (vaginitis, 40%, 
cervicitis 22% and pelvic inflammatory disease 9%) and genital prolapse (54%) were also 
discovered.  
 
NOTES: 
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ABSTRACT No. 3
 
Insights into modeling techniques for schistosomiasis and sexually transmitted infections 
 
Munyaradzi Paul Mapingure1  
 
1University of Zimbabwe, P.O.Box MP 167, Mount Pleasant, Harare, Zimbabwe 
 
Sexually transmitted infections (STIs) have been found to be a risk factor for HIV transmission. 
Likewise genital schistosomiasis has been found to be associated with HIV in rural Zimbabwe. 
The mechanisms for HIV propagation across the genital epithelium in females are believed to 
be similar to that of STIs (breach of mucosal barrier, recruitment of immunoactive cells or 
upregulation of HIV receptors).  
 
Schistosomiasis is transmitted through water contact from childhood, whereas the STIs are 
transmitted by the very same mechanisms as HIV. The populations at risk of STIs (sexual risk 
behaviour) and schistosomiasis (exposure to infested water) may be completely different, or 
overlap as found in Zimbabwe.   
 
Mathematical modeling has provided new insights on rates of spread of infection, epidemic 
trends, and effects of treatment. The effect of decreasing prevalence or eradication of the 
schistosomiasis may be estimated by modeling provided the confounding factors are fed into 
the mathematical formulas. Sexually Transmitted Disease Simulation Model (STDSIM) is one 
such model that allows simultaneous and interactive simulation of up to sixteen different STIs. 
 
Herpes simplex virus type 2 has been suggested to account for 8-31% of the HIV cases. The 
prevalence of HSV-2 is 20-65%. Likewise genital schistosomiasis prevalence is approximately 
50% and may therefore account for a number of HIV cases in rural areas. The modeling process 
could be useful in determining whether mass/treatment for schistosomiasis should be 
implemented in countries affected by the two epidemics. 
 
 
NOTES: 
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ABSTRACT No. 4
Clinical Findings in Gemale Genital Schistosomiasis After Controlling for Confounders 
and Severity of Infection 
 
Eyrun Floerecke Kjetland1, Patricia D. Ndhlovu2, Takafira Mduluza3, Exenevia Gomo4, 
Lovemore Gwanzura, Peter R. Mason, Edith Nyaradzai Kurewa, Nicholas Midzi5, Henrik Friis,  
Svein Gunnar Gundersen6 
 
1 Medisinsk divisjon, Infeksjonsmedisinsk avdeling, Ullevål Universitetssykehus, 0407 Oslo, 
Norway 
2 Metabolic and Clinical Trials Unit, Camden Mews Day Hospital, 5 Camden Mews, London, 
NW1 9DB, UK 
3 Department of Biochemistry, University of Zimbabwe, Box MP 167, Mount Pleasant, Harare, 
Zimbabwe 
4 Research Support Centre, College of Medicine, University of Malawi, Private Bag 360, 
Chichiri, Blantyre 2, Malawi 
5 National Institute of Health Research, Box CY 573, Causeway, Harare,  Zimbabwe 
6 Research unit, Sorlandet Hospital HF and Agder University College, Kristiansand, Norway 
 
Up to 75% of women with urinary schistosomiasis have Schistosoma haematobium ova in the 
genitals. The study aimed to describe the prevalence of gynecological S. haematobium infection 
and to differentiate the disease from sexually transmitted infections (STIs). Gynecological and 
laboratory investigations for S. haematobium and STIs were performed in 527 women between 
the age of 20 and 49 in rural Zimbabwe. Genital homogenous yellow and/ or grainy sandy 
patches, the commonest type of genital pathology, were identified in 243 (46%) women. Grainy 
sandy patches were significantly associated with S. haematobium ova only. Genital S. 
haematobium ova was also significantly associated with homogenous yellow sandy patches, 
mucosal bleeding, and abnormal blood vessels. Ova presence was not a predictor for ulcers, 
papillomata, leukoplakia, polyps, or cell atypia. Mucosal sandy patches seem to be 
pathognomonic for S. haematobium infection in the female genitals. Coexistence of ova and 
other lesions may not be causal. 
 
 
NOTES: 
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ABSTRACT No. 5
 
 
Male genital schistosomiasis: Symptoms and semen analysis 
 
Peter DC Leutscher1,2, Charles-Emile Ramarokoto1, Steen Hoffmann3, Jørgen S Jensen3, Vero L 
Ramaniraka1, Bodo S Randrianasolo1, Clairette Raharisolo1, Voahangy E Ravaoalimalala1, 
René Migliani1 and Niels O Christensen2 
 
1.Institut Pasteur de Madagascar, BP 1274, 101 Antananarivo, Madagascar 
2. DBL - Centre for Health and Research, Faculty of Life Sciences, University of Copenhagen, 
3.Statens Serum Institut, Artillerivej 5, DK-2300, Copenhagen, Denmark 
 
Peter DC Leutscher1,2, Erik Høst3 and Claus M Reimert2 
 
1.The Pasteur Institute, Antananarivo, Madagascar 
2. DBL - Centre for Health and Research, Faculty of Life Sciences, University of Copenhagen, Denmark 
3.Department of Fertility, Herlev Universityhospital, Copenhagen, Denmark 
 
Symptoms 
Background. Urogenital schistosomiasis and sexually transmitted infections (STIs) co-exist in 
most Schistosoma haematobium endemic areas in Sub-Saharan Africa, which poses a diagnostic 
challenge for health care providers in the management of patients with urogenital complaints, 
particular in settings with lack of adequate laboratory service. 
 
Methods. Urogenital symptoms were researched by use of a semi-structured questionnaire at 
baseline and successively in follow-up surveys after systematic STI and anti-schistosoma 
treatment as part of a community-based study of reproductive tract morbidity in 236 men aged 
15 to 49 years living in a S. haematobium endemic area in northern Madagascar. 
 
Results. Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium and/or 
Trichomonas vaginalis were diagnosed in 17% of the S. haematobium infected men. Half of the 
men tested positive for an STI or for S. haematobium were asymptomatic. No symptoms were 
associated to STIs found in men. Gross hematuria, dysuria, and painful ejaculation were 
associated with S. haematobium infection. 
 
Conclusions. The study confirms the common co-existence of STIs and urogenital 
schistosomiasis. The rationale for empiric anti-schistosoma treatment of younger adults in 
S.haematobium endemic areas, by the addition of a single dose of praziquantel to existing anti-
STI regimens, is discussed. 
 
Semen Analysis 
Background: The seminal vesicles are as frequently as the bladder a site for egg-induced 
inflammation in Schistosoma haematobium infected men. Egg excretion in ejaculate has been 
found associated with increased seminal leukocyte count and cytokine levels. The objective of 
this study was to evaluate the effect of male genital schistosomiasis (MGS) on spermatozoa 
DNA fragmentation. 
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Methods: Semen samples from men aged 15 to 49 years with positive egg excretion in urine 
were examined by an immune-histochemical staining method for terminal 3’-OH prior to anti-
schistosoma treatment and 5 months later. Seminal ova, spermatozoa, and leukocyte counts 
were performed, in addition to measurement of seminal eosinophil cationic protein (ECP) level. 
 
Results: In the cohort of 27 S. haematobium infected men, the mean apoptotic rate at baseline 
was 6.8%. Fifteen (56%) individuals were detected with ova in semen. There were no cases of 
oligospermia (≤20 millions spermatozoa/mL) and azospermia. Pyospermia (> 1 mill. 
spermatozoa) was observed in 5 (17%) men. Apoptotic rate was significantly correlated to 
seminal ECP level. At follow-up, the prevalence and intensity of egg excretion in urine and in 
semen declined significantly in conjunction with a significant reduction in mean apoptotic rate 
to 3.3%. 
 
Conclusion: The study demonstrated that the spermatogenic cells in S.haematobium infected 
men undergo apoptosis, which seems responsive to anti-schistosoma treatment. Egg induced 
inflammation in the seminal vesicles could be underlying mechanism. Further studies are 
needed to evaluate the consequences of S.haematobium infection on male fertility. 
 
 
 
NOTES: 
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ABSTRACT No. 6
 
Clinical, parasitological and ultrasound study of female genital Schistosomiasis, due to 
Schistosoma haematobium infection in an endemic Nigerien village, in 2005.  
 
 
Garba A1, Lamine M1, Tohon Z3, Alfari A2 
 
1RISEAL / SCI, 333, avenue des Zarmakoye, BP.13724, Niamey, Niger 
2Programme national de lutte contre la bilharziose et les géohelminthes, Niamey, Niger 
3Centre de recherche médicale et sanitaire (CERMES), B.P. 10887, Niamey, Niger 
 
 
Schistosoma haematobium is a major endemic disease in Niger.  However, the impact of the parasite 
on the gynecological tract is not well known.  Our study aimed to increase the knowledge about 
Schistosoma haematobium infection and its relationship with reproductive health in a 
community of women in a hyper-endemic village of Niger.   
 
This cross-sectional study took place in April 2005 in the village of Kaou located near a 
temporary pond in the northern Niger.  The study population was women of child-bearing age, 
having lived in the village for at least one year, and who had given their consent to participate 
in the study.  The study subjects were randomly selected after a census was done of the entire 
village.  The study included an interview, a general clinical and gynecological examination, a 
visual examination of the urine, a urine examination using Hemastix® for evidence of 
microhematuria, a parasitological examination after filtration of 10 ml of urine for S. 
haematobium eggs, and two smear tests of genital secretion for direct examination and for 
Gram’s method, a hemoglobin test using the Hemocue® machine, and a ultrasound examination 
using the WHO Niamey protocol.  
 
In total, 120 women were included in the study.  The age group of 15-25 years (45%) and 26-35 
years (35%) were the most represented.  The overall prevalence of infection of S. haematobium 
was 32.2%, macrohematuria was 10.4%, and microhematuria was 44.4%.  Anemia prevalence 
was 68.4%, and was significantly higher in women infected with schistosomiasis (p<0.05). 
 
The overall frequency of clinical urological symptoms was 66.7% for reported pain during 
urination, 25.8% for pollakiuria, and 55.8% for lower pubic area pain. All the symptoms were 
more frequently reported in women infected with schistosomiasis than in those not infected, but 
the difference was not statistically significant.  Leucorrhoea, abdominal pain, pruritus vulvae, 
and dyspareunia were the most commonly reported gynecological complaints, with a frequency 
of 82.5%, 58.3%, 55% and 46.3% respectively.  Overall, in 51.5% of the cases, the cervix had 
lesions. Infertility and delivery complications were reported by 24.2% and 17.5% of the 
subjects respectively, a history of abortions by 13.3% and premature delivery by 5.8% of the 
subjects. The evidence of S.haematobium eggs was negative in all the smear tests.   In the 
vaginal secretions of the subjects we found bacillus with positive Gram coloration in 47.2%, 
leukocytes in 20.4%, cocci with positive Gram coloration in 12.9%, diplococcus in 10.2% and 
yeast in 5.6%.  
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The obstetrical and gynecological manifestations of schistosomiasis are very evident. The 
treatment with praziquantel in endemic zones will contribute to the reduction in the morbidity 
caused by schistosomiasis in the female genital tract.   
 
Key words: Female genital schistosomiasis, Schistosoma haematobium, obstetrical-
gynecological tract, women of childbearing age, Niger 
 
 
NOTES: 
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ABSTRACT No. 7
Pre- and Post-treatment ultrasonographical findings in the urogenital organs in 
Schistosoma haematobium infected women and men 
 
CE Ramarokoto1, P. Leutscher2, BS Randrianasolo1, V Ramaniraka1, R Migliani1, NO 
Christensen2, VE Ravaoalimalala1,3 
 
1Institut Pasteur de Madagascar, Antananarivo, Madagascar 
2 Danish Bilharziasis Laboratory, Copenhague, Denmark 
3 Malagasy Ministry of Health, Madagascar 
 
Background: Ultrasonography (US) has so far not been used systematically in studies of 
Schistosoma haematobium associated pathology in the reproductive organs, although the 
technique seems potentially useful.   
 
Methods: US was applied in this community-based study to assess Schistosoma haematobium 
associated pathology the uro-genital organs in women and men. Individuals (105 women and 
116 men) from the high-endemic Sirama village with positive egg excretion in urine were 
compared to non-infected individuals (100 women and 118 men) from the low-endemic 
Mataipako village with negative results for both parameters. In addition to examination of the 
urinary tract by transabdominal US, the female genitals were examined by transvaginal route, 
whereas the male genitals were examined by transrectal and transscrotal routes.  
 
Results: Pathology of the urinary tract was significantly more prevalent at baseline among 
women and men in the high-endemic Sirama village than in the Mataipako village. There was 
no difference in the prevalence and nature of abnormalities in the female genital tract, including 
volumetric measurements, between the two study populations. Significant higher proportions of 
men in the Sirama village compared to the Mataipako village were detected with 
hyperechogenic and calcified lesions in the seminal vesicles and the prostate, whereas there was 
no difference with respect to the external genitals. The mean size (the production of length and 
width) of the seminal vesicles was significantly larger in the Sirama village. Six months after 
anti-schistosoma treatment, the prevalence of urinary tract abnormalities had declined 
significantly for women and men in the Sirama village. Abnormalities and volumetric 
measurements of the internal male genitals also declined significantly.  
 
Conlusion: The study has provided new insight into uro-genital morbidity in S.haematobium 
infected men and women, but the clinical significance of these findings remain unclear. 
 
 
NOTES: 
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ABSTRACT No. 8
 
Schistosomiasis and HIV in Zimbabwe – the MUSH study 
 
Per Kallestrup1 
 
1 Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 
2100 Copenhagen, Denmark 
 
The Mupfure Schistosomiasis and HIV (MUSH) study is the result of a collaborative research 
project between the National Institute of Health Research (former Blair Research Institute), 
Harare, Zimbabwe and Department of Infectious Diseases, Rigshospitalet, Copenhagen, 
Denmark.   
 
Apart from hosting 85% of the worlds estimated 200 million people living with schistosomiasis, 
the Sub-Saharan region of Africa also has the highest prevalence as well as total numbers of 
HIV-1 infected individuals. Schistosomiasis may by interference with the course of the HIV 
infection have great influence on the health of a large number of HIV infected individuals. Thus 
this study focused on the possible interaction between schistosomiasis and HIV in co-infected 
individuals. The study had three main objectives: 1) To compare the intensity of schistosomiasis 
between HIV negative individuals and HIV infected patients and describe the relationship 
between schistosomiasis intensity and immunodeficiency among the HIV infected, 2) To 
determine whether treatment of schistosomiasis with praziquantel is effective in immune 
suppressed HIV infected individuals, 3) To determine whether treatment of schistosomiasis 
with praziquantel has effect on the course of the HIV infection in co-infected individuals, 
evaluated by surrogate markers of disease progression. 
 
All data were collected through the same field study conducted from October 2001 to June 2003 
in Mupfure and adjacent areas in Shamva District, Mashonaland Central Province in Zimbabwe. 
To our knowledge it is the largest study exploring interactions of schistosomiasis and HIV to 
date and the first to be designed as a randomised controlled trial, which led to the creation of the 
MUSH Cohort.  
In a cross-sectional survey a total of 2281 adults residing in the study area were screened 
regarding schistosomiasis and HIV status and a full set of information including three urine 
samples, one stool sample and HIV status were obtained from 1545 individuals. Among the 
total study population 26.3% were HIV positive and 43.4% were infected with schistosomiasis. 
379 individuals were subsequently enrolled into a prospective cohort to ensure complementary 
data including quantitative measures of intensity of schistosomiasis and HIV related 
immunodeficiency and in order to carry out the treatment intervention studies. 
 
There was no difference in egg excretion between HIV positive and HIV negative individuals 
infected with S. haematobium, S. mansoni or both. Moderately to severe HIV induced immuno-
deficiency did not impair egg excretion of S. haematobium or S. mansoni in HIV positive 
individuals co-infected with low intensity schistosomiasis. Treatment of schistosomiasis with 
praziquantel resulted in similar and satisfactory reductions in egg counts between HIV positive 
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and HIV negative individuals, but HIV positive individuals cleared significantly less CAA – a 
schistosome gut-associated antigen indicative of active infection. Praziquantel may thus be less 
capable of inducing eradication of adult schistosomes in the immuno-compromised host. 
Schistosomiasis was over a three-month follow-up period associated with an increase in HIV 
replication among co-infected and successful treatment of schistosomiasis arrested this increase 
in viral load. Treatment of schistosomiasis also increased CD4-counts irrespective of HIV 
status. 
 
In conclusion our findings suggest that control of schistosomiasis will not only reduce the 
substantial morbidity directly associated with schistosomiasis, but may simultaneously 
moderate an otherwise accelerated progression of HIV infection in the co-infected individual. In 
the current attempts to rollout anti-retroviral therapy, appropriate attention should be given to 
simultaneous schistosomiasis control and special guidelines for treatment of schistosomiasis in 
HIV co-infected individuals may need to be developed. 
 
Perspectives of the results of the MUSH study 
The results of our study provide important new insight that may prove relevant to several 
aspects of the interaction of concurrent infections and HIV in general and the dynamics of 
schistosomiasis and HIV co-infection in particular. 
 
Primarily it is of importance to bring concurrent infections into focus to ensure appropriate 
attention not only to the impact these may have on the progression of HIV disease but equally 
to how HIV induced immunodeficiency may alter the pathogenesis as well as the efficacy of 
established treatment strategies of these concomitant ailments. Furthermore is the scale and 
severity of the HIV pandemic in the developing world a direct threat to the very fabric of 
society and the health infrastructure specifically. The magnitude of the epidemic has in places 
overwhelmed and paralyzed the health institutions to a degree where the care for other 
otherwise manageable infections fails. Renewed emphasis on the possible combined benefit of 
treating concurrent infections and the possible development of more efficient treatment 
strategies may induce much needed optimism and enthusiasm among the patients and 
stakeholders in the health sector. 
 
Regarding the actual findings of our study the prospects evidently focus on individuals with 
schistosomiasis and HIV co-infection and thus areas where schistosomiasis is endemic and HIV 
prevalence may be high as well. Contrary to prior reports our results indicate that moderately to 
severe HIV induced immunodeficiency does not impair egg excretion of S. haematobium or 
S.mansoni in HIV positive individuals co-infected with low intensity schistosomiasis. This 
implies that egg counts can still be trusted when diagnosing schistosomiasis also in a population 
with high prevalence of S. haematobium or S.mansoni. In contrast egg counts may be less 
trustworthy when it comes to monitoring of efficacy of praziquantel in the treatment of 
schistosomiasis in the HIV co-infected host. Our praziquantel treatment study revealed that 
although similar and satisfactory reductions in egg counts were obtained between HIV positive 
and HIV negative individuals, the HIV positive individuals cleared significantly less CAA than 
HIV negative following treatment with praziquantel. This could be an indication of surviving 
worms due to reduced efficacy of praziquantel in the immunocompromised host and raises the 
question if the conventional treatment regimen is adequate for HIV patients. 
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Finally and encouragingly our results indicate that it makes good sense to treat schistosomiasis 
also among the HIV infected. Not only does it reduce the health impact of the schistosomiasis 
infection alone but it also seems to arrest an otherwise accelerated HIV replication. If our 
results can be confirmed in new independent studies, this may have wide implications since 
many of the regions of the world that currently carry the brunt of the HIV pandemic are also 
prone to high occurrences of schistosomiasis and often particularly so in areas that are less 
developed and therefore may be difficult to reach with anti-retroviral treatment programs.  Here 
initiatives to control schistosomiasis could prove beneficial in slowing down HIV progression. 
Additionally such initiatives could potentially delay the time for initiation of anti-retroviral 
therapy and thereby postpone and possibly reduce the need for anti-retroviral treatment. In the 
current worldwide quest to roll-out anti-retroviral treatment the advantage gained from treating 
candidates for anti-retroviral therapy for their concurrent schistosomiasis should not be missed. 
Although we acknowledge that ART currently is the only strategy that has the potential to offer 
durable benefits for HIV patients it is our hope that appropriate attention will be devoted to the 
impact of schistosomiasis as well as other potentially harmful ailments in the design of ART 
initiatives. 
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The prevalence of urinary schistosomiasis and HIV in females living in a rural community 
of Zimbabwe: does age matter? 
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Recto: Urinary schistosomiasis and HIV in females in Zimbabwe 
 
A cross-sectional study was conducted on 544 women living in Mupfure rural area of 
Zimbabwe to determine whether infection with urinary schistosomiasis is associated with HIV 
infection. Schistosoma haematobium infection was examined in urine samples and HIV 
infection was determined in sera. The prevalence of S. haematobium infection was highest 
(60%) in women below 20 years of age and declined to 29% in the oldest age group (P < 
0.001). Overall, women infected with urinary schistosomiasis had an HIV prevalence of 33.3%, 
whilst women without urinary schistosomiasis had an HIV prevalence of 25.6% (P = 0.053). 
Women above the age of 35 years and infected with urinary schistosomiasis had a significantly 
higher HIV prevalence (37.5%) than those without urinary schistosomiasis (16.8%; P < 0.001). 
 
KEYWORDS  Schistosoma haematobium, HIV, urinary schistosomiasis, age 
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Male genital schistosomiasis and HIV 
 
Peter DC Leutscher1,2, Mette Pedersen3, Clairette Raharisolo1, Jørgen S Jensen4, Steen 
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Ullum3,6 
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Background: To provide indicative data validating the hypothesized association between male 
genital schistosomiasis and HIV transmission, a study was conducted amongst men living in an 
area where urogenital schistosomiasis and STIs co-exist.  
 
Methods: This study investigated the seminal inflammatory response to egg-infestation of the 
urogenital organs in 240 ejaculate donating men aged 15 to 49 years living in a Schistosoma 
haematobium endemic area of Madagascar.  
 
Results: In 29 (12%) subjects detected with ≥5 ova excretion in the ejaculate, leucocytospermia 
(>106 leucocytes/mL), seminal lymphocytes and eosinophil leucocytes, were each significantly 
more prevalent compared to 74 (31%) S. haematobium negative subjects (P<.01). In addition, 
seminal levels of interleukin (IL)-4, IL-6, IL-10, and tumor necrosis factor (TNF-α) were 
significantly higher amongst seminal egg excreting subjects compared to negative subjects 
(P<.001). Sexually transmitted infections (STIs) with Neisseria gonorrhoeae, Chlamydia 
trachomatis, Mycoplasma genitalium and/or Trichomonas vaginalis did not act as confounders 
for the observed associations. At six months follow-up after systematic anti-schistosomiasis and 
STI syndrome treatment at baseline, the prevalence of seminal leucocytes decreased 
significantly amongst the previously seminal egg positive subjects. The same tendency was 
observed for the post-treatment levels of cytokines.  
 
Conclusion: Numerous studies have already shown an association between STI associated 
genital inflammation and HIV propagation. Therefore, this study suggests that male urogenital 
schistosomiasis may constitute a risk factor for HIV transmission due to the egg-induced 
inflammation in the semen-producing pelvic organs. 
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In a rural Zimbabwean community where we had investigated 83% of the eligible community 
members and found S. haematobium related lesions in 46% of the women, HIV in 29% and 
herpes simplex type- 2 (HSV-2) in 65%. We wished to determine the association between 
female genital Schistosoma (S.) haematobium infection and human immunodeficiency virus 
(HIV). Women between the ages of 20 and 49 years who were sexually active, non-pregnant, 
non-menopausal, permanent residents (>3 years residency) were included in a cross-sectional 
study was done with a one-year follow-up. Gynecological and laboratory investigations were 
performed for S. haematobium and HIV. Sexually transmitted infections, demographic and 
urogenital history were analysed as confounders.  
HIV was found in 41% (29/ 70) of women with laboratory proven genital schistosomiasis as 
opposed to 26% HIV positive (96/ 375) in the schistosomal ova negative group (OR 2.1; 95%CI 
1.2- 3.5; p= 0.008). In multivariate analysis S. haematobium infection of the genital mucosa 
was significantly associated with HIV seropositivity (adjusted OR 2.9, 95%CI 1.11- 7.5, 
p=0.030). All 7 women who became HIV positive in the study period (seroincidence 3.1%) had 
signs of S. haematobium at baseline. In accordance with other studies HIV was significantly 
associated with HSV-2 (OR 3.0, 95%CI 1.7- 5.3, p<0.001), syphilis and human papillomavirus. 
The highest HIV prevalence (45%) was found in the 25-29 years age group. Women with 
genital schistosomiasis had an almost 3-fold risk of having HIV in this rural Zimbabwean 
community.  
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Female genital schistosomiasis in Madagascar: Symptoms and Pelvic Exam  
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Symptoms 
Background. Urogenital schistosomiasis and sexually transmitted infections (STIs) co-exist in 
most Schistosoma haematobium endemic areas in Sub-Saharan Africa, which poses a diagnostic 
challenge for health care providers in the management of patients with urogenital complaints, 
particular in settings with lack of adequate laboratory service. 
 
Methods. Urogenital symptoms were researched by use of a semi-structured questionnaire at 
baseline and successively in follow-up surveys after systematic STI and anti-schistosoma 
treatment as part of a community-based study of reproductive tract morbidity in 253 women 
aged 15 to 49 years living in a S. haematobium endemic area in northern Madagascar. 
 
Results. Thirty five percent of the S. haematobium infected women were co-infected with 
Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium and/or Trichomonas 
vaginalis. Half of the women tested positive for an STI or for S. haematobium were 
asymptomatic. Among the women, vaginal discharge and dysuria were associated with an STI. 
Gross hematuria, dysuria, and pelvic discomfort were associated with S. haematobium 
infection. 
 
Conclusions. The study confirms the common co-existence of STIs and urogenital 
schistosomiasis. The rationale for empiric anti-schistosoma treatment of younger women in 
S.haematobium endemic areas, by the addition of a single dose of praziquantel to existing anti-
STI regimens, is discussed. 
 
Pelvic exam 
Background: Schistosoma haematobium is endemic in most parts of African continent and 
represents a major public health problem. Although the urinary bladder is the primary target 
organ for the migrating worm pairs, the genitals in both women and men are also commonly 
affected. A cross-sectional study was conducted to assess abnormalities associated to S. 
haematobium infection in the female lower genital tract, and to evaluate effect of anti-
schistosoma treatment.   
 
Methods: Women aged 15 to 49 years old with positive egg excretion in urine living in a small 
cluster of villages in high-endemic Sirama sugarcane plantation were compared to women with 
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negative egg excretion in the low-endemic Mataipako village. Pelvic examination by use of 
colposcopy was carried out at baseline, at T 1 month (after systematic STI treatment) and T 6 
months (after systematic anti-schistosoma treatment).  
 
Results. 152 women in Sirama and 122 women in Mataipako were included at baseline. One 
third of the women in both settings were diagnosed with an STI (Neisseria gonorrhoeae, 
Chlamydia trachomatis, Mycoplasma genitalium and/or Trichomonas vaginalis). Except from 
vaginal discharge no other findings were associated to STI. Cervicitis by inspection and cervical 
inflammation by colposcopy were significantly more frequent in Mataipako, whereas 
punctation/mosaicism was significant more frequent in Sirama. Sandy patches were observed 
3.8% of the women in Sirama versus in 1.6% in Mataipako.Erosion/ulceration and 
polyp/tumour were also infrequently observed in the two study sites.  
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The effect of S. haematobium ova on mucosal blood vessels and cells with special attention 
to susceptibility to HIV transmission.  An immunohistochemical and histopathological 
study. 
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Genital Schistosoma haematobium could be an important co-factor in HIV transmission. Genital 
ulcer disease and cervicitis have been shown to recruit immunologically active cells. Immune 
activation may increase both the number of local target cells, as well as the density of 
chemokine receptors. S. mansoni is associated with increased expression of HIV co-receptors 
CCR5 and CXCR4 in peripheral blood CD4+ T cells and monocytes. Furthermore, in vitro 
mononuclear cells from humans with schistosomiasis are more susceptible to HIV infection, 
than are cells from humans without schistosomiasis. Moreover, eosinophils have been found to 
be susceptible to productive infection with HIV. The phenomena have not yet been explored in 
genital cells in persons with schistosomiasis. By clinical observation, genital schistosomiasis is 
associated with mucosal bleeding. It has been postulated that products secreted by S. mansoni 
ova may promote angiogenesis, comparable to what is seen during the development of 
malignant tumours. In a cross-sectional study an almost threefold HIV-prevalence has been 
found in women with genital schistosomiasis. We hypothesise that immunactivation and 
neovascularisation in genital schistosomal infection facilitate HIV transmission. In archive 
biopsies taken from the female genital tract we wish to explore biological factors which may 
influence the transmission of HIV in women with schistosomiasis, provided ethical permission 
is granted. We wish to (1) establish the presence of immune cells, and identify by polyclonal 
protein detection (2) HIV receptors and (3) neovascularisation. The results may shed light on 
the susceptibility of women who have genital schistosomiasis 
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ABSTRACT No. 15
The  Clinical And Bedside Investigations of Genital Schistosimiasis in Women: Unfeasible, 
Uncomfortable, Imprecise, Dangerous and Futile? 
 
Eyrun Floerecke Kjetland1 
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The crushed bedside biopsy of the cervix is deemed to be the golden standard for the 
parasitological diagnosis of female genital S. haematobium. Biopsies however, are taken for 
histology, the ova are located in focal clusters and may be missed by histological cuts. 
Moreover, women in schistosomiasis and HIV endemic areas might neither have a choice of 
whether to have intercourse nor the courage to suggest use of a barrier contraceptive method. 
Hence, taking a biopsy remains an HIV transmission risk until the inflicted wound has healed, 
raising ethical concern.  
 
Wet smears and PAP smears may make a contribution to the diagnosis but the sensitivity is low. 
Up to 41% of women in endemic areas may have involvement of the lower reproductive tract 
without schistosome ova in urine. Hence, urinary filtration or dipsticks are insensitive indicators 
for genital S. haematobium. Increased levels of eosinophil cationic protein, Neopterin or IgA in 
cervico-vaginal lavage have only limited value in the diagnosis of female genital 
schistosomiasis. The PCR diagnosis, new for the genital tract, will be discussed in another 
abstract. 
 
The co-existence of ova with clinical entities such as the numerous STDs makes it difficult to 
single out a cause of a current lesion or discharge. S. haematobium ova is associated with sandy 
patches in the genital mucosa, abnormal blood vessels and concomitant contact bleeding, and 
the clinical appearance of genital schistosomiasis may be mistaken for malignancy. Furthermore 
ova have been found in conjunction with ulcers, papillomatous tumours, leukoplakia, and 
polyps. However, S. haematobium ova may be found in almost every organ of the body and 
there may sometimes be no inflammatory reaction. Hence, the coexistence of S. haematobium 
ova and lesions or discharge may not always be causal. 
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Assessment Of Eosinophil Cationic Protein (ECP) As A Possible Diagnostic Marker For 
Female Genital Schistosomiasis Among Women Living In A Schistosoma Haematobium 
Endemic Area 
 
Midzi, N1., Ndhlovu , PD2., Nyanga, L., Kjetland, EF3., Reimert, CM4., Vennervald, BJ4., 
Gomo, E5., Mudenge, G., Friis, H., Gundersen, SG6., Mduluza, T.7 
 
1 National Institute of Health Research, Box CY 573, Causeway, Harare , Zimbabwe 
2 Metabolic and Clinical Trials Unit, Camden Mews Day Hosptial, 5 Camden Mews, London 
NW1 9DB, United Kingdom 
3 Medisinsk divisjon, Infeksjonsmedisinsk avdeling, Ullevål Universitetssykehus, 0407 Oslo,  
Norway 
4 DBL – Centre for International Health Research and Development, Faculty of Life Sciences 
Thorvaldsensvej 57, 1871 Frederiksberg C 
5 Research Support Centre, College of Medicine, University of Malawi, Private Bag 360, 
Chichiri, Blantyre 2, Malawi 
6 Research unit, Sorlandet Hospital HF and Agder University College, Kristiansand, Norway 
7 Department of Biochemistry, University of Zimbabwe, Box MP 167, Mount Pleasant, Harare 
Zimbabwe 
 
Eosinophil cationic protein (ECP) levels were measured in vaginal lavage extracts from 518 
Zimbabwean reproductive women, age range 15-49years, to assess the potential use of ECP as a 
diagnostic marker for female genital schistosomiasis (FGS). One hundred and fifty women had 
confirmed FGS status. These included 77 cases, women who had ova in genital tissue, and 73 
controls, women who had no ova in genital tissue. Participants were treated with praziquantel at 
baseline and were followed up at 3 and 15 months post treatment surveys. ECP levels were 
determined using the enzyme linked immunosorbent assay (ECP-ELISa). ECP levels from 18 
Norwegian women were used to calculate the diagnostic values of the test. FGS was diagnosed 
from the study population using genital biopsy and smears. Women were also diagnosed for 
urinary schistosomiasis using the urine filtration technique. The prevalence of urinary 
schistosomiasis was 39% at baseline and this declined to 8% and 6% at 3 and 15 months post 
treatment surveys respectively. There was a higher mean ECP level in women with FGS, 
889.3ng/ml compared to the endemic control group, p = 0.027 (95% CI: 227.3-490.9). Mean 
ECP levels declined at 3 months post treatment following treatment of infected individuals. 
There was no correlation between ECP levels and tissue ova density, and urine egg intensity. 
The sensitivity and specificity for the ECP-ELISA test were 35%, 80% respectively. Our results 
indicate that FGS causes an inflammatory immune response that increases ECP levels in genital 
fluid. Treatment of schistosomiasis results in regression of pathology and a decline in ECP 
levels. How ever other factors such as allergy and microbial infection could also be responsible 
for increased ECP levels in genital mucosa. These conditions will affect the validity of the test 
in diagnosis of FGS. 
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Multiplex real-time PCR for the diagnosis of female genital schistosomiasis. 
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Real-time PCR for the detection of intestinal parasites in faecal samples is increasingly used in 
diagnostic laboratories 1 and also as a tool in epidemiological studies 2. Recently a multiplex 
real-time PCR was described for the detection Schistosoma DNA in stool and urine 3. Designed 
primers and probes for Schistosoma mansoni and S. haematobium were combined as a 
multiplex with primers and probe for the detection of an internal control. The multiplex real-
time PCR essay showed 100% specificity and high sensitivity. Additionally, the outcome of the 
multiplex real-time PCR, defined by Cycle threshold-values, showed a significant correlation 
with quantitative microscopic examination of human stool and urine samples.  
The Schistosoma real-time PCR is also assumed to be a valuable tool in the diagnosis of female 
genital schistosomiasis (FGS). FGS, caused by infection of the parasite S. haematobium, is 
considered to be a major health problem in sub-Saharan Africa. Epidemiological and clinical 
studies on FGS traditionally rely on the microscopic detection of parasite eggs in biopsies, wet 
smears and PAP smears of the cervix. However, sensitivity of these diagnostic tools proved to 
be insufficient for diagnosing FGS. Moreover, the risk of HIV transmission for the patient and 
her partner increases through the inflicted wound from the biopsy 4.  
Already several sexually transmitted micro-organisms are diagnosed by PCR on DNA isolated 
from cervical washings. These analyses can easily be extended with real-time PCR for 
Schistosoma haematobium, by using the same isolated DNA samples. The quantitative outcome 
of the real-time PCR can provide a better prognosis of FGS and evaluate the success of a 
therapy.  
Moreover, for case studies conducted in remote areas where cold chain is not available, 
collected PAP smears can be stored in 70 % alcohol at room temperature until transported to a 
laboratory with real-time PCR facilities. The simple sample collection procedure in 
combination with the high throughput potential of real-time PCR can provide a powerful 
diagnostic tool for epidemiological and clinical studies on FGS in remote areas. 
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Eosinophil Cationic Protein (ECP), Soluble Egg Antigen (SEA), and Circulating Anodic 
Antigen (CAA) in Male Genital Schistosomiasis 
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Background: Epidemiological and clinical data regarding genital schistosomiasis are sparse. 
This is, in part, due to a lack of validated markers for genital infection. Urine egg count, the 
traditional marker of urinary S. haematobium infection, may not necessarily be representative 
for infection of the genitals.  
 
Methods: Circulating anodic antigen (CAA) in serum, in addition to eosinophil cationic protein 
(ECP) and soluble egg antigen (SEA) were investigated in urine and semen samples from 
Schistosoma haematobium infected men aged 15 to 49 years before and six months after 
praziquantel treatment.  
 
Results: A mutual positive correlation was observed between CAA, urinary ECP and SEA and 
egg count, except in comparison ECP with CAA. Seminal egg count was positive in 32 (48%) 
of 67 men providing two semen samples. A marked variation in seminal egg excretion was 
observed. Mean geometric levels of ECP and SEA were significantly higher in egg positive 
semen samples than in negative samples. SEA level in semen correlated positively with seminal 
egg count. Parallel to a significant decrease in urinary and seminal egg excretion after 
treatment, levels of ECP and SEA in urine and in semen, plus CAA also declined significantly.  
 
Conclusion: ECP and SEA in semen constitutes supplementary diagnostic markers of male 
urogenital schistosomiasisBackground: Epidemiological and clinical data regarding genital 
schistosomiasis are sparse. This is, in part, due to a lack of validated markers for genital 
infection. Urine egg count, the traditional marker of urinary S. haematobium infection, may not 
necessarily be representative for infection of the genitals.  
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Urinary schistosomiasis is known to be associated with lesions in the female genital organs, 
particularly with the presence of “sandy patches” in the lower genital tract. This study sought to 
determine the effect of treatment with praziquantel on gynecological schistosomiasis in 
residents of a Schistosoma haematobium endemic area. A cohort study was conducted among 
20- 49 years old women in rural Zimbabwe. The shape and size of lesions were mapped pre- 
treatment, and 3 and 12 months following treatment. Ova of S. haematobium were looked for in 
cytology smears, wet mounts, biopsies, urine and stool. Specimens were collected for detection 
of sexually transmitted diseases and cancer.  
 
At baseline almost half of the 527 women included in the study had sandy patches. Although 
urinary ova excretion decreased following treatment (OR, 10.3 95% CI 3.8- 27.8, p<0.001), 
praziquantel was not associated with a significant reduction in genital lesions or contact 
bleeding (p=0.31-0.94). Sandy patches remained strongly associated with contact bleeding and 
vessel abnormalities even after treatment. Findings were independent of HIV status. Such 
lesions, common, and apparently refractory to treatment for at least 12 months, may be an 
important risk factor for both the acquisition and transmission of the human immunodeficiency 
virus.  
 
NOTES: 
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ABSTRACT No. 21
 
Preventive Chemotherapy Strategy For Control Of Schistosomiasis In Integration With 
Other Neglected Tropical Diseases: WHO Perspective 
 
1Likezo Mubila,  Barrysson  Andriamahefazafy,  Dirk Engels, Pamela Mbabazi and Lester 
Chitsulo 
 
1WHO AFRO, Parirenyatwa Hospital, Division of Disease Control and Prevention, OTD Unit, P.O.Box 773 BE 
Harare, Zimbabwe 
 
Schistosomiasis continues to contribute to the burden of neglected tropical diseases with about 
200 million people affected world wide. Early infection may go unnoticed but cumulative and 
long-term infections result in pathology in some organs of the body causing unrinary tract 
fibrosis, hydronephrosis, liver enlargement and associated ascites and bladder cancer as very 
late stage complications. Progression to these conditions can be retarded if cumulation of 
infection is stopped. The aim of preventive chemotherapy is to avert the widespread morbidity 
that results from heavy and prolonged infection with helminths. Early and regular 
administration of recommended antihelminthic drugs reduces the occurence, extent, severity 
and long-term consequences of morbity, and also contributes to reduction in transmission of 
infection. Morbidity control therefore is the WHO recommended strategy for schistosomiasis 
control achieved by large scale and regular treatment with praziquantel of the high risks groups 
in communities. However it is important that mass drug administrations be combined with other 
tools/activities that help to sustain the effect of the drugs. In this respect other supporting 
interventions such as environmental measures need to be equally addressed. 
 
Large scale treatment delivery interventions are a strategy used in other disease control 
programmes as well, some of which share the same target groups, notably soil transmitted 
helmithiasis, lymphatic filariasis, onchocerciasis and - to some extent - trachoma. In order to 
improve the efficiency and cost-effectiveness in the implementation of these programmes and 
synergy in their outcomes, coordination and collaboration is recommended during 
implementation of interventions where the diseases overlap, , therefore leading to streamlining 
in the implementation of activities and synergism in outcomes of  activities. As a working 
definition "integration" is defined as the creation of linkages among existing programmes for 
the purpose of improving delivery of interventions within the existing health system using 
resources available to the programmes concerned.  Ultimately, the goal of promoting integration 
is to improve the effectiveness  of the health system and not creating parallel or alternative 
structures. 
 
NOTES: 
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ABSTRACT No. 22
Schistosomiasis in young women and girls in KwaZulu Natal, South Africa  
 
M Taylor1, E F Kjetland2 
 
1 Dept. of Public Health Medicine, Nelson Mandela School of Medicine, University of KwaZulu  
Natal, Private Bag 7, Congella 4013, Durban , South Africa 
2 Medisinsk divisjon, Infeksjonsmedisinsk avdeling, Ullevål Universitetssykehus, 0407 Oslo, 
Norway 
 
Backgound.  S. haematobium eggs have been found in the uterine cervix, vagina and vulva, as 
well as the urinary tract, but women may have genital schistosomiasis without urinary findings. 
Genital schistosomiasis is associated with a three fold increase in HIV prevalence. Aim. To 
investigate genital schistosomiasis in young women and girls and the effectiveness of regular 
treatment with praziquantel in reducing HIV incidence. Objectives. 1) To investigate the 
clinical manifestations of genital schistosomiasis in young rural South African women after 
controlling for STDs.  2) To investigate clinical signs and symptoms in young girls predictive of 
acute genital schistosomiasis. 3) To investigate schistosomiasis antibodies and antigens 
predictive of adult genital schistosomiasis. 4) To investigate whether schistosomiasis increases 
the expression of HIV receptors CCR5 and CXCR4 in blood and genital cells. 5) To investigate 
whether genital schistosomiasis infection increases HIV viral load and genital shedding. 6) To 
investigate whether genital schistosomiasis increases HIV incidence. 7) To investigate whether 
early and repeated treatment with praziquantel will reduce the susceptibility to HIV resulting in 
decreased HIV receptor expression, genital viral load and HIV incidence. Method.  a) A cross 
sectional study and b) a prospective case control study are planned in rural KwaZulu-Natal 
(Ugu and Ilembe Districts). a) 888  sexually active women  16- 20 years of age will be 
interviewed for urogenital symptoms, obstetric history, and current and past STDs and 
investigated for schistosomiasis, blood, and photocolposcopic examination, pap-smears and 
cervico-vaginal lavage will be undertaken. b) 1407 pre-pubertal girls 10-12y will be enrolled in 
the study, complete a questionnaire and will be followed up for schistosomiasis, interviewed 
and treated with praziquantel annually until 550 have become sexually active, when 
schistosomiasis and blood will be investigated and photocolposcopic examination, pap-smears 
and cervico-vaginal lavage will be undertaken. Ethical clearance for the study has been obtained 
and informed consent will be obtained.  
 
 
NOTES: 
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ABSTRACT No. 24
 
Impacts of Climate Change on Health 
 
M.J.Chimbari 
 
National University of Science and Technology, Box AC 939, Ascot, Bulawayo, Zimbabwe; 
email: mjchimbari@gmail.com, mjchimbari1799@nust.ac.zw 
 
The phenomenon of climate change at global and local levels is now internationally accepted 
and the following predictions have been made for Africa (IPCC TAR, 2001); i) global mean 
temperatures of between 1.5oC and 6oC may be reached by 2100, ii) temperatures in Africa may 
increase by 0.2 oC to more than 0.5 oC per decade and the semi-arid regions of the Sahara and 
central and South Africa will be the most affected, iii) sea levels may rise by 15-95 cm by 2100, 
iv) Southern Africa will become hotter and drier, while Central Africa will become hotter and 
wetter and v) the probability of having extreme weather events (droughts, floods, typhoons, etc 
) will increase. While the climatic changes documented in the IPCC TAR 2001 are not disputed, 
it is their immediate direct impacts that are questioned with the long and sustained impacts 
being a subject of debate as it is difficult to establish a causal relationship for the long term 
impacts. This paper describes some of the impacts that climate change has had and is likely to 
have on human health, particularly vector borne diseases; argues why developing countries or 
African countries, in particular, will be affected most by climate change; and describes the 
coping strategies in place and recommended for minimizing the impacts of climate change on 
human health. The paper concludes that i) the impacts of climate change on human health are 
complex and require a transdisciplinary approach in dealing with them, ii) that vector borne 
diseases are likely to be influenced much more by climate change, iii) that sound strategies for 
adapting to the impacts of climate change are well documented with little action on the ground, 
iv) that there are serious challenges that may frustrate the efforts to minimize  impacts of 
climate but also many opportunities that could be exploited; and v) that there needs to be more 
than political will among governments if adaptation activities are to be sustained.  
 
 
NOTES: 
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ANNEX 4 
 
Newspaper articles from Zambian newspapers published in connection with the 
workshop 
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ANNEX 5 
 
 
SPEECH BY THE HON. MINISTER OF HEALTH, 
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ON THE OFFICIAL OPENING OF THE INTERNATIONAL WORKSHOP ON 
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Directors from the Ministry of Health;  
Officials from DBL- Center for Health Research and Development;  
Representatives from the Research Network for Schistosomiasis in Africa, 
The chairperson of the organising committee; distinguished scientists; colleagues and 
friends, 
All scientists, distinguished ladies and gentlemen. 
May I simply say all protocols observed.  
 
 
 
It gives me a great pleasure on behalf of the Zambian Government to address you all at 
this historic event – the international workshop on “Schistosomiasis and Reproductive 
Health”.  
 
Distinguished guests, I am reliably informed that this morning and the next 3 days, this 
gathering will have presentations and discussions elucidating how far we are in the 
knowledge about genital schistosomiasis and the impact on reproductive health. The 
aim of the workshop is to identify the possible impact that genital schistosomiasis might 
have on public health and the implication for national programs for the control of 
schistosomiasis, HIV and sexually transmitted disease; a topic of great importance not 
only in Zambia but the whole of Africa. This should eventually help us to identify the 
research areas that need to be further addressed. 
 
 
 Distinguished guests, schistosomiasis can cause significant morbidity and yet it is 
preventable and treatable. In fact one of the most important diseases caused by 
helminths in Zambia is schistosomiasis which has continued to retard human 
development in our society through ailments like malnutrition, poor growth in children, 
anaemia, kidney failure, cancer of the urinary bladder and lesions in the male and 
female genital organs. The latter may have a devastating impact on the reproductive 
health of people and may be a risk factor for the spread of HIV infection. This as we all 
know can seriously destroy national economy through loss of man hours due to ill 
health not to mention human suffering, and as such the control of schistosomiasis 
becomes a priority.  
 
I am pleased to see that the issues to be discussed at this workshop include clinical 
aspects of genital schistosomiasis, with presentation of important findings from various 
field studies; the possible impact of genital schistosomiasis on the spread of HIV 
infection and the problems related to the diagnosis of genital schistosomiasis. 
Schistosomiasis in the context of reproductive health is a complex issue and calls for a 
multi-disciplinary approach. I am therefore very pleased to know that this workshop 
includes not only clinicians and biomedical researches but also social scientists and 
colleagues directly involved in the implementation of schistosomiasis control 
programmes.  
All of these issues, ladies and gentlemen, will, I am sure, stimulate debate and 
discussion amongst the scientists, professionals and specialists present at this 
conference.  
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Distinguished guests, you may wish to know that in Zambia, bilharzia affects more than 
2 million people, most of them being the poorest and most disadvantages people. 
Bilharzia is prevalent countrywide and school children are the most commonly and 
heavily infected group. The disease is also common in fishing communities, irrigation 
workers, farmers, women and young girls.  
To address the problem, the government, through Ministry of Health formed a Bilharzia 
Control Program in collaboration with the Ministry of Education, The University of 
Zambia, various cooperating partners such as the WHO, The Danish Bilharziasis 
Laboratory now DBL, the Schistosomiasis Control Initiative of the Imperial College of 
London and other line ministries, to name but a few.  
 
My hope is that your discussions at this meeting will lead to suggestions as how to 
improve control strategies in existing control programs for schistosomiasis, HIV and 
STD’s and thereby to a strengthening of the collaboration between scientist and control 
managers working in these fields. I trust that this workshop will be both memorable and 
useful. 
 
Let me take this opportunity to thank the DBL-Center for Health Research and 
Development for giving the Zambia the opportunity to host this workshop. We are also 
grateful that DBL and the Schistosomiasis Control Initiative (SCI) have provided 
financial support for this important meeting. 
 
In conclusion, let me take this opportunity to welcome all delegates to our country, 
especially if this is your first visit to Zambia. Welcome to Lusaka and we hope that you 
will find Zambia stimulating and exciting.  
I hope you have pleasant stay in our country and I trust that you will take time from 
your busy schedule to visit some of our world-renowned tourist attractions.  
I wish you all the best in your deliberations and I thank you all.  
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